https://trial.medpath.com/news/ectrims-2024-high-dose-vitamin-d-can-help-delay-progression-to-ms 2024-09-21T15:47:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ectrims-2024-high-dose-vitamin-d-can-help-delay-progression-to-ms 2024-09-21T15:47:20+00:00 weekly 0.7 https://trial.medpath.com/news/niger-latest-african-country-to-launch-malaria-vaccine-medical-xpress 2024-09-21T15:07:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/niger-latest-african-country-to-launch-malaria-vaccine-medical-xpress 2024-09-21T15:07:35+00:00 weekly 0.7 https://trial.medpath.com/news/lenalidomide-obinutuzumab-combo-yields-promising-results-in-relapsed-nhl 2024-09-21T14:26:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lenalidomide-obinutuzumab-combo-yields-promising-results-in-relapsed-nhl 2024-09-21T14:26:19+00:00 weekly 0.7 https://trial.medpath.com/news/fight-retinal-blindness-spain-report-3-clinical-outcomes-of-vascular-endothelial-growth 2024-09-21T14:08:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fight-retinal-blindness-spain-report-3-clinical-outcomes-of-vascular-endothelial-growth 2024-09-21T14:08:21+00:00 weekly 0.7 https://trial.medpath.com/news/armour-s-mononine-monoclonal-factor-ix-approved-by-fda-pink-sheet 2024-09-21T14:05:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/armour-s-mononine-monoclonal-factor-ix-approved-by-fda-pink-sheet 2024-09-21T14:05:33+00:00 weekly 0.7 https://trial.medpath.com/news/ibcn-2024-eg-70-detalimogene-voraplasmid-a-novel-non-viral-intravesical-gene 2024-09-21T14:02:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ibcn-2024-eg-70-detalimogene-voraplasmid-a-novel-non-viral-intravesical-gene 2024-09-21T14:02:58+00:00 weekly 0.7 https://trial.medpath.com/news/new-clinical-trial-in-kenya-could-move-needle-in-cancer-treatment-the-standard-health 2024-09-21T13:48:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-clinical-trial-in-kenya-could-move-needle-in-cancer-treatment-the-standard-health 2024-09-21T13:48:09+00:00 weekly 0.7 https://trial.medpath.com/news/gene-and-cell-therapy-approaches-hold-promise-for-usher-syndrome-cgtlive-r 2024-09-21T13:13:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gene-and-cell-therapy-approaches-hold-promise-for-usher-syndrome-cgtlive-r 2024-09-21T13:13:28+00:00 weekly 0.7 https://trial.medpath.com/news/ozempic-glp-1-drugs-may-prevent-3400-heart-attacks-strokes-a-year-healthline 2024-09-21T12:23:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ozempic-glp-1-drugs-may-prevent-3400-heart-attacks-strokes-a-year-healthline 2024-09-21T12:23:19+00:00 weekly 0.7 https://trial.medpath.com/news/expert-dermatologist-outlines-key-diagnostic-criteria-for-urticaria-at-maui-derm-conference 2024-09-21T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/expert-dermatologist-outlines-key-diagnostic-criteria-for-urticaria-at-maui-derm-conference 2024-09-21T12:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/study-highlights-variable-efficacy-of-aspirin-dosing-during-pregnancy 2024-09-21T11:35:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-highlights-variable-efficacy-of-aspirin-dosing-during-pregnancy 2024-09-21T11:35:23+00:00 weekly 0.7 https://trial.medpath.com/news/pharma-stock-roundup-fda-approvals-for-lly-mrk-azn-jnj-drugs-yahoo-finance 2024-09-21T11:12:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharma-stock-roundup-fda-approvals-for-lly-mrk-azn-jnj-drugs-yahoo-finance 2024-09-21T11:12:45+00:00 weekly 0.7 https://trial.medpath.com/news/president-and-ceo-harris-todd-sold-394441-worth-of-shares-16307-units-at-24-19 2024-09-21T10:44:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/president-and-ceo-harris-todd-sold-394441-worth-of-shares-16307-units-at-24-19 2024-09-21T10:44:46+00:00 weekly 0.7 https://trial.medpath.com/news/high-throughput-identification-of-repurposable-neuroactive-drugs-with-potent-anti-nature 2024-09-21T10:19:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/high-throughput-identification-of-repurposable-neuroactive-drugs-with-potent-anti-nature 2024-09-21T10:19:08+00:00 weekly 0.7 https://trial.medpath.com/news/first-line-combo-yields-strong-results-in-advanced-sarcoma 2024-09-21T10:11:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-line-combo-yields-strong-results-in-advanced-sarcoma 2024-09-21T10:11:02+00:00 weekly 0.7 https://trial.medpath.com/news/chief-medical-officer-conner-edward-r-exercised-4790-shares-at-a-strike-of-4-20-and-sold 2024-09-21T09:51:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chief-medical-officer-conner-edward-r-exercised-4790-shares-at-a-strike-of-4-20-and-sold 2024-09-21T09:51:57+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approval-propels-zvra-to-52-week-high-adma-cprx-tvtx-also-reach-new-peaks 2024-09-21T08:27:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approval-propels-zvra-to-52-week-high-adma-cprx-tvtx-also-reach-new-peaks 2024-09-21T08:27:23+00:00 weekly 0.7 https://trial.medpath.com/news/ncpa-intensifies-campaign-for-pbm-reform-as-congressional-deadline-looms 2024-09-21T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ncpa-intensifies-campaign-for-pbm-reform-as-congressional-deadline-looms 2024-09-21T08:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/study-shingles-reactivation-could-occur-in-rare-cases-following-rzv-pharmacy-times 2024-09-21T07:26:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-shingles-reactivation-could-occur-in-rare-cases-following-rzv-pharmacy-times 2024-09-21T07:26:01+00:00 weekly 0.7 https://trial.medpath.com/news/capivasertib-shows-promise-in-er-her2-metastatic-breast-cancer-with-pik3ca-mutations 2024-09-21T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/capivasertib-shows-promise-in-er-her2-metastatic-breast-cancer-with-pik3ca-mutations 2024-09-21T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/global-metabolic-disruption-discovered-in-sma-patients-n-acetylneuraminic-acid-shows-treatment-potential 2024-09-21T06:28:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/global-metabolic-disruption-discovered-in-sma-patients-n-acetylneuraminic-acid-shows-treatment-potential 2024-09-21T06:28:00+00:00 weekly 0.7 https://trial.medpath.com/news/apellis-shares-dip-as-mizuho-cuts-price-target-keeps-neutral-rating-investing-com-canada 2024-09-21T05:12:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/apellis-shares-dip-as-mizuho-cuts-price-target-keeps-neutral-rating-investing-com-canada 2024-09-21T05:12:15+00:00 weekly 0.7 https://trial.medpath.com/news/biohaven-announces-conference-call-to-discuss-topline-pivotal-study-results-in-pr-newswire 2024-09-21T05:08:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biohaven-announces-conference-call-to-discuss-topline-pivotal-study-results-in-pr-newswire 2024-09-21T05:08:05+00:00 weekly 0.7 https://trial.medpath.com/news/novel-pan-immune-inflammation-nomogram-shows-promise-in-predicting-epithelial-ovarian-cancer-outcomes 2024-09-21T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-pan-immune-inflammation-nomogram-shows-promise-in-predicting-epithelial-ovarian-cancer-outcomes 2024-09-21T05:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/rachna-shroff-on-advanced-hepatocellular-carcinoma-anlotinib-plus-penpulimab-vs-sorafenib 2024-09-21T04:54:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rachna-shroff-on-advanced-hepatocellular-carcinoma-anlotinib-plus-penpulimab-vs-sorafenib 2024-09-21T04:54:50+00:00 weekly 0.7 https://trial.medpath.com/news/simvastatin-fails-to-reduce-disease-progression-in-phase-3-ms-stat2-trial-of-secondary 2024-09-21T04:41:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/simvastatin-fails-to-reduce-disease-progression-in-phase-3-ms-stat2-trial-of-secondary 2024-09-21T04:41:10+00:00 weekly 0.7 https://trial.medpath.com/news/university-of-arkansas-for-medical-sciences-receives-2-2-million-grant-to-study-efferocytosis 2024-09-21T04:25:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/university-of-arkansas-for-medical-sciences-receives-2-2-million-grant-to-study-efferocytosis 2024-09-21T04:25:39+00:00 weekly 0.7 https://trial.medpath.com/news/rethinking-beta-blocker-use-following-acute-myocardial-infarction 2024-09-21T03:17:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rethinking-beta-blocker-use-following-acute-myocardial-infarction 2024-09-21T03:17:28+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-investigational-new-drug-application-for-cd-001-in-oncology 2024-09-21T02:50:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-clears-investigational-new-drug-application-for-cd-001-in-oncology 2024-09-21T02:50:46+00:00 weekly 0.7 https://trial.medpath.com/news/a-precision-medicine-initiative-sponsored-by-the-national-cancer-institute-aims-to-improve 2024-09-21T02:43:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/a-precision-medicine-initiative-sponsored-by-the-national-cancer-institute-aims-to-improve 2024-09-21T02:43:57+00:00 weekly 0.7 https://trial.medpath.com/news/ibcn-2024-elucidating-the-response-rates-to-additional-bcg-implications-for-clinical-trial-design 2024-09-21T02:33:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ibcn-2024-elucidating-the-response-rates-to-additional-bcg-implications-for-clinical-trial-design 2024-09-21T02:33:50+00:00 weekly 0.7 https://trial.medpath.com/news/cybin-misses-end-of-summer-goal-for-phase-3-study-start-green-market-report 2024-09-21T02:25:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cybin-misses-end-of-summer-goal-for-phase-3-study-start-green-market-report 2024-09-21T02:25:26+00:00 weekly 0.7 https://trial.medpath.com/news/on-the-move-dr-michael-lyons-upstate-business-journal 2024-09-21T00:15:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/on-the-move-dr-michael-lyons-upstate-business-journal 2024-09-21T00:15:42+00:00 weekly 0.7 https://trial.medpath.com/news/novo-s-phase-ii-miss-in-obesity-oral-amps-up-pressure-on-bd-biocentury 2024-09-21T00:05:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novo-s-phase-ii-miss-in-obesity-oral-amps-up-pressure-on-bd-biocentury 2024-09-21T00:05:21+00:00 weekly 0.7 https://trial.medpath.com/news/actinium-pharmaceuticals-announces-publication-of-results-from-the-phase-3-sierra-trial 2024-09-20T23:59:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/actinium-pharmaceuticals-announces-publication-of-results-from-the-phase-3-sierra-trial 2024-09-20T23:59:02+00:00 weekly 0.7 https://trial.medpath.com/news/revolutionizing-oncology-insights-on-the-fda-s-project-optimus-and-dose-optimization 2024-09-20T23:40:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/revolutionizing-oncology-insights-on-the-fda-s-project-optimus-and-dose-optimization 2024-09-20T23:40:32+00:00 weekly 0.7 https://trial.medpath.com/news/stereotactic-vs-hypofractionated-radiotherapy-for-inoperable-stage-i-non-small-cell-lung-cancer 2024-09-20T22:48:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/stereotactic-vs-hypofractionated-radiotherapy-for-inoperable-stage-i-non-small-cell-lung-cancer 2024-09-20T22:48:36+00:00 weekly 0.7 https://trial.medpath.com/news/new-cancer-research-breakthrough-has-the-potential-to-save-lives-nbc-boston 2024-09-20T22:38:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-cancer-research-breakthrough-has-the-potential-to-save-lives-nbc-boston 2024-09-20T22:38:15+00:00 weekly 0.7 https://trial.medpath.com/news/director-gagnon-robert-e-sold-365-worth-of-shares-131-units-at-2-79-decreasing-direct 2024-09-20T22:18:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/director-gagnon-robert-e-sold-365-worth-of-shares-131-units-at-2-79-decreasing-direct 2024-09-20T22:18:46+00:00 weekly 0.7 https://trial.medpath.com/news/ibcn-2024-a-randomized-phase-ii-trial-comparing-single-dose-perioperative-instillation 2024-09-20T21:53:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ibcn-2024-a-randomized-phase-ii-trial-comparing-single-dose-perioperative-instillation 2024-09-20T21:53:26+00:00 weekly 0.7 https://trial.medpath.com/news/maeve-lowery-md-on-a-novel-bifunctional-antibody-in-advanced-hepatocellular-carcinoma 2024-09-20T21:47:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/maeve-lowery-md-on-a-novel-bifunctional-antibody-in-advanced-hepatocellular-carcinoma 2024-09-20T21:47:27+00:00 weekly 0.7 https://trial.medpath.com/news/extended-estrogen-suppression-safe-in-breast-cancer-inside-precision-medicine 2024-09-20T21:30:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/extended-estrogen-suppression-safe-in-breast-cancer-inside-precision-medicine 2024-09-20T21:30:55+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-cuts-radiation-time-dramatically-sanford-health-news 2024-09-20T21:25:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trial-cuts-radiation-time-dramatically-sanford-health-news 2024-09-20T21:25:44+00:00 weekly 0.7 https://trial.medpath.com/news/rock-you-like-a-migraine-opdp-issues-notice-of-violation-for-misleading-representations 2024-09-20T21:06:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rock-you-like-a-migraine-opdp-issues-notice-of-violation-for-misleading-representations 2024-09-20T21:06:16+00:00 weekly 0.7 https://trial.medpath.com/news/this-week-at-fda-asca-guidances-new-clinical-trial-guidances-and-more-raps 2024-09-20T20:54:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/this-week-at-fda-asca-guidances-new-clinical-trial-guidances-and-more-raps 2024-09-20T20:54:08+00:00 weekly 0.7 https://trial.medpath.com/news/after-july-surge-fda-approvals-for-gi-settle-into-summer-lull-what-you-may-have-missed 2024-09-20T20:42:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/after-july-surge-fda-approvals-for-gi-settle-into-summer-lull-what-you-may-have-missed 2024-09-20T20:42:17+00:00 weekly 0.7 https://trial.medpath.com/news/acelyrin-straight-move-to-phase-3-ted-studies-makes-it-must-watch-nasdaq-slrn 2024-09-20T20:40:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acelyrin-straight-move-to-phase-3-ted-studies-makes-it-must-watch-nasdaq-slrn 2024-09-20T20:40:38+00:00 weekly 0.7 https://trial.medpath.com/news/me-therapeutics-to-begin-testing-of-first-mrna-formulations-from-nanovation-pharmabiz-com 2024-09-20T20:29:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/me-therapeutics-to-begin-testing-of-first-mrna-formulations-from-nanovation-pharmabiz-com 2024-09-20T20:29:20+00:00 weekly 0.7 https://trial.medpath.com/news/tectonic-therapeutic-reports-findings-from-phase-ia-trial-of-tx45 2024-09-20T20:24:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tectonic-therapeutic-reports-findings-from-phase-ia-trial-of-tx45 2024-09-20T20:24:45+00:00 weekly 0.7 https://trial.medpath.com/news/stanford-car-t-solid-tumor-study-enrolls-first-pediatric-patient 2024-09-20T20:22:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/stanford-car-t-solid-tumor-study-enrolls-first-pediatric-patient 2024-09-20T20:22:30+00:00 weekly 0.7 https://trial.medpath.com/news/promising-results-from-phase-1-2-trial-of-nkt2152-for-advanced-kidney-cancer 2024-09-20T20:07:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/promising-results-from-phase-1-2-trial-of-nkt2152-for-advanced-kidney-cancer 2024-09-20T20:07:25+00:00 weekly 0.7 https://trial.medpath.com/news/nervgen-pharma-to-present-at-the-unite-2-fight-paralysis-19th-annual-science-advocacy 2024-09-20T20:02:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nervgen-pharma-to-present-at-the-unite-2-fight-paralysis-19th-annual-science-advocacy 2024-09-20T20:02:28+00:00 weekly 0.7 https://trial.medpath.com/news/fibrobiologics-engages-southern-star-research-as-cro-in-australia-biospace 2024-09-20T20:02:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fibrobiologics-engages-southern-star-research-as-cro-in-australia-biospace 2024-09-20T20:02:26+00:00 weekly 0.7 https://trial.medpath.com/news/ipsen-s-iqirvo-r-elafibranor-approved-in-the-european-union-as-first-new-treatment-for 2024-09-20T19:31:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ipsen-s-iqirvo-r-elafibranor-approved-in-the-european-union-as-first-new-treatment-for 2024-09-20T19:31:21+00:00 weekly 0.7 https://trial.medpath.com/news/cetylpyridinium-chloride-inhibits-hepatocellular-carcinoma-growth-and-metastasis-through-plos 2024-09-20T17:58:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cetylpyridinium-chloride-inhibits-hepatocellular-carcinoma-growth-and-metastasis-through-plos 2024-09-20T17:58:55+00:00 weekly 0.7 https://trial.medpath.com/news/eqs-adhoc-brain-biotech-ag-concludes-royalty-monetization-deal-for-up-to-eur-128-88 2024-09-20T17:53:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eqs-adhoc-brain-biotech-ag-concludes-royalty-monetization-deal-for-up-to-eur-128-88 2024-09-20T17:53:07+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-nasal-spray-as-first-self-administered-flu-vaccine-healio 2024-09-20T17:22:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-nasal-spray-as-first-self-administered-flu-vaccine-healio 2024-09-20T17:22:29+00:00 weekly 0.7 https://trial.medpath.com/news/us-fda-approves-zevra-s-genetic-disorder-treatment-yahoo-finance 2024-09-20T17:16:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/us-fda-approves-zevra-s-genetic-disorder-treatment-yahoo-finance 2024-09-20T17:16:41+00:00 weekly 0.7 https://trial.medpath.com/news/novo-nordisk-and-corbus-pharmaceutical-stocks-plummet-benzinga-benzinga 2024-09-20T17:15:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novo-nordisk-and-corbus-pharmaceutical-stocks-plummet-benzinga-benzinga 2024-09-20T17:15:06+00:00 weekly 0.7 https://trial.medpath.com/news/ema-announces-positive-opinion-for-sb15-opuviz-samsung-bioepis-and-biogen 2024-09-20T16:57:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ema-announces-positive-opinion-for-sb15-opuviz-samsung-bioepis-and-biogen 2024-09-20T16:57:09+00:00 weekly 0.7 https://trial.medpath.com/news/astellas-receives-approval-from-the-european-commission-for-vyloytm-zolbetuximab-in 2024-09-20T16:54:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astellas-receives-approval-from-the-european-commission-for-vyloytm-zolbetuximab-in 2024-09-20T16:54:56+00:00 weekly 0.7 https://trial.medpath.com/news/intravascular-lithotripsy-a-clinical-trial-snapshot 2024-09-20T16:42:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/intravascular-lithotripsy-a-clinical-trial-snapshot 2024-09-20T16:42:51+00:00 weekly 0.7 https://trial.medpath.com/news/fda-alert-pulmonology-drug-approvals-and-recalls-medical-device-updates 2024-09-20T16:41:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-alert-pulmonology-drug-approvals-and-recalls-medical-device-updates 2024-09-20T16:41:53+00:00 weekly 0.7 https://trial.medpath.com/news/press-release-tolebrutinib-demonstrated-a-31-delay-in-time-to-onset-of-confirmed-sanofi 2024-09-20T16:32:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/press-release-tolebrutinib-demonstrated-a-31-delay-in-time-to-onset-of-confirmed-sanofi 2024-09-20T16:32:13+00:00 weekly 0.7 https://trial.medpath.com/news/ecu-health-pioneers-with-fda-approved-elupro-bioenvelope-in-pacemaker-implantation 2024-09-20T15:48:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ecu-health-pioneers-with-fda-approved-elupro-bioenvelope-in-pacemaker-implantation 2024-09-20T15:48:05+00:00 weekly 0.7 https://trial.medpath.com/news/novo-nordisk-s-1bn-oral-weight-loss-drug-shows-promise-but-raises-questions-in-phase-iia-trial 2024-09-20T15:34:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novo-nordisk-s-1bn-oral-weight-loss-drug-shows-promise-but-raises-questions-in-phase-iia-trial 2024-09-20T15:34:42+00:00 weekly 0.7 https://trial.medpath.com/news/novo-nordisk-s-monlunabant-expectations-dashed-by-phase-ii-data-scrip-citeline 2024-09-20T15:14:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novo-nordisk-s-monlunabant-expectations-dashed-by-phase-ii-data-scrip-citeline 2024-09-20T15:14:01+00:00 weekly 0.7 https://trial.medpath.com/news/phase-3-mogwai-trial-to-test-azathioprine-as-first-line-treatment-for-mogad 2024-09-20T15:10:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-3-mogwai-trial-to-test-azathioprine-as-first-line-treatment-for-mogad 2024-09-20T15:10:51+00:00 weekly 0.7 https://trial.medpath.com/news/phase-iii-cabinet-trial-cabozantinib-in-advanced-neuroendocrine-tumors 2024-09-20T15:09:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-iii-cabinet-trial-cabozantinib-in-advanced-neuroendocrine-tumors 2024-09-20T15:09:00+00:00 weekly 0.7 https://trial.medpath.com/news/initial-in-vivo-validation-of-novel-cancer-therapeutics-using-ai-drug-target-review 2024-09-20T15:05:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/initial-in-vivo-validation-of-novel-cancer-therapeutics-using-ai-drug-target-review 2024-09-20T15:05:42+00:00 weekly 0.7 https://trial.medpath.com/news/rx-rundown-maxcyte-roche-and-more-medical-marketing-and-media 2024-09-20T14:44:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rx-rundown-maxcyte-roche-and-more-medical-marketing-and-media 2024-09-20T14:44:34+00:00 weekly 0.7 https://trial.medpath.com/news/henlius-biotech-s-drug-nears-eu-approval-tipranks-com 2024-09-20T14:43:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/henlius-biotech-s-drug-nears-eu-approval-tipranks-com 2024-09-20T14:43:28+00:00 weekly 0.7 https://trial.medpath.com/news/inavolisib-shows-promising-disease-control-rates-safety-in-patients-with-pik3ca-mutated 2024-09-20T14:36:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inavolisib-shows-promising-disease-control-rates-safety-in-patients-with-pik3ca-mutated 2024-09-20T14:36:36+00:00 weekly 0.7 https://trial.medpath.com/news/new-listings-in-avma-veterinary-clinical-trials-registry-september-2024 2024-09-20T14:34:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-listings-in-avma-veterinary-clinical-trials-registry-september-2024 2024-09-20T14:34:17+00:00 weekly 0.7 https://trial.medpath.com/news/meeting-highlights-from-the-committee-for-medicinal-products-for-human-use-chmp-16-19 2024-09-20T14:33:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/meeting-highlights-from-the-committee-for-medicinal-products-for-human-use-chmp-16-19 2024-09-20T14:33:39+00:00 weekly 0.7 https://trial.medpath.com/news/apellis-eye-drug-again-turned-back-in-europe-biopharma-dive 2024-09-20T14:28:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/apellis-eye-drug-again-turned-back-in-europe-biopharma-dive 2024-09-20T14:28:26+00:00 weekly 0.7 https://trial.medpath.com/news/an-optimized-strategy-triggered-at-the-2nd-immunization-visit-to-prevent-hiv-acquisition-by 2024-09-20T14:28:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/an-optimized-strategy-triggered-at-the-2nd-immunization-visit-to-prevent-hiv-acquisition-by 2024-09-20T14:28:21+00:00 weekly 0.7 https://trial.medpath.com/news/aligos-reports-positive-data-from-phase-iia-mash-treatment-trial 2024-09-20T14:25:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aligos-reports-positive-data-from-phase-iia-mash-treatment-trial 2024-09-20T14:25:18+00:00 weekly 0.7 https://trial.medpath.com/news/targeted-therapies-novel-antibodies-and-immunotherapies-in-advanced-non-small-cell 2024-09-20T14:19:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/targeted-therapies-novel-antibodies-and-immunotherapies-in-advanced-non-small-cell 2024-09-20T14:19:52+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-as-common-drug-shrinks-fatal-and-aggressive-brain-tumours-raising-hopes-of-a-cure 2024-09-20T14:17:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-as-common-drug-shrinks-fatal-and-aggressive-brain-tumours-raising-hopes-of-a-cure 2024-09-20T14:17:13+00:00 weekly 0.7 https://trial.medpath.com/news/novo-s-next-gen-cb1-drug-leads-to-weight-loss-in-phase-ii-but-neuropsychiatric-events-reported 2024-09-20T14:11:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novo-s-next-gen-cb1-drug-leads-to-weight-loss-in-phase-ii-but-neuropsychiatric-events-reported 2024-09-20T14:11:36+00:00 weekly 0.7 https://trial.medpath.com/news/atezolizumab-venetoclax-and-obinutuzumab-in-richter-transformation-diffuse-large-b 2024-09-20T14:02:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/atezolizumab-venetoclax-and-obinutuzumab-in-richter-transformation-diffuse-large-b 2024-09-20T14:02:46+00:00 weekly 0.7 https://trial.medpath.com/news/revolution-or-mirage-controversy-surrounds-new-alzheimer-s-drugs-medical-xpress 2024-09-20T13:12:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/revolution-or-mirage-controversy-surrounds-new-alzheimer-s-drugs-medical-xpress 2024-09-20T13:12:07+00:00 weekly 0.7 https://trial.medpath.com/news/darzalex-r-daratumumab-based-quadruplet-regimen-receives-positive-chmp-opinion-for 2024-09-20T13:09:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/darzalex-r-daratumumab-based-quadruplet-regimen-receives-positive-chmp-opinion-for 2024-09-20T13:09:32+00:00 weekly 0.7 https://trial.medpath.com/news/novel-btk-inhibitor-lp-168-under-investigation-in-china-for-r-r-mantle-cell-lymphoma 2024-09-20T13:03:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-btk-inhibitor-lp-168-under-investigation-in-china-for-r-r-mantle-cell-lymphoma 2024-09-20T13:03:13+00:00 weekly 0.7 https://trial.medpath.com/news/alpha-tau-announces-fda-approval-of-ide-to-initiate-multi-center-investigator-morningstar 2024-09-20T12:56:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alpha-tau-announces-fda-approval-of-ide-to-initiate-multi-center-investigator-morningstar 2024-09-20T12:56:13+00:00 weekly 0.7 https://trial.medpath.com/news/where-will-amgen-be-in-5-years-aol-com 2024-09-20T12:49:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/where-will-amgen-be-in-5-years-aol-com 2024-09-20T12:49:11+00:00 weekly 0.7 https://trial.medpath.com/news/biosyngen-best-in-class-next-generation-tumor-infiltrating-lymphocyte-til-technology 2024-09-20T12:32:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biosyngen-best-in-class-next-generation-tumor-infiltrating-lymphocyte-til-technology 2024-09-20T12:32:26+00:00 weekly 0.7 https://trial.medpath.com/news/press-release-dupixent-recommended-for-eu-approval-by-the-chmp-to-treat-eosinophilic-sanofi 2024-09-20T12:06:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/press-release-dupixent-recommended-for-eu-approval-by-the-chmp-to-treat-eosinophilic-sanofi 2024-09-20T12:06:28+00:00 weekly 0.7 https://trial.medpath.com/news/kangpu-completed-bridging-clinical-study-of-kpg-818-in-china-pr-newswire 2024-09-20T12:02:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kangpu-completed-bridging-clinical-study-of-kpg-818-in-china-pr-newswire 2024-09-20T12:02:23+00:00 weekly 0.7 https://trial.medpath.com/news/marinus-pharmaceuticals-to-highlight-clinical-progress-and-commercial-launch-stock-titan 2024-09-20T12:01:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/marinus-pharmaceuticals-to-highlight-clinical-progress-and-commercial-launch-stock-titan 2024-09-20T12:01:20+00:00 weekly 0.7 https://trial.medpath.com/news/merck-receives-positive-eu-chmp-opinions-for-keytruda-r-pembrolizumab-regimens 2024-09-20T11:36:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merck-receives-positive-eu-chmp-opinions-for-keytruda-r-pembrolizumab-regimens 2024-09-20T11:36:14+00:00 weekly 0.7 https://trial.medpath.com/news/abbvie-receives-positive-chmp-opinion-for-mirvetuximab-soravtansine-elahere-r-for 2024-09-20T11:34:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/abbvie-receives-positive-chmp-opinion-for-mirvetuximab-soravtansine-elahere-r-for 2024-09-20T11:34:51+00:00 weekly 0.7 https://trial.medpath.com/news/apellis-receives-negative-chmp-opinion-for-pegcetacoplan-for-geographic-atrophy-ga-in 2024-09-20T11:26:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/apellis-receives-negative-chmp-opinion-for-pegcetacoplan-for-geographic-atrophy-ga-in 2024-09-20T11:26:55+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-lse-azn-gains-fda-approval-for-fasenra-in-egpa-boosting-revenue 2024-09-20T10:47:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-lse-azn-gains-fda-approval-for-fasenra-in-egpa-boosting-revenue 2024-09-20T10:47:22+00:00 weekly 0.7 https://trial.medpath.com/news/syncona-s-beacon-therapeutics-presents-trial-results-at-conference-morningstar 2024-09-20T10:10:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/syncona-s-beacon-therapeutics-presents-trial-results-at-conference-morningstar 2024-09-20T10:10:23+00:00 weekly 0.7 https://trial.medpath.com/news/gprc5d-emerges-as-promising-target-in-multiple-myeloma-clinical-trials 2024-09-20T09:48:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gprc5d-emerges-as-promising-target-in-multiple-myeloma-clinical-trials 2024-09-20T09:48:02+00:00 weekly 0.7 https://trial.medpath.com/news/dad-s-epilepsy-med-use-won-t-harm-his-kids-study 2024-09-20T09:28:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dad-s-epilepsy-med-use-won-t-harm-his-kids-study 2024-09-20T09:28:01+00:00 weekly 0.7 https://trial.medpath.com/news/novel-strategies-emerge-to-transform-cold-tumors-into-immunotherapy-responsive-hot-tumors 2024-09-20T09:20:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-strategies-emerge-to-transform-cold-tumors-into-immunotherapy-responsive-hot-tumors 2024-09-20T09:20:47+00:00 weekly 0.7 https://trial.medpath.com/news/cspc-pharmaceutical-s-new-hypertension-drug-trials-approved-tipranks-com 2024-09-20T09:16:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cspc-pharmaceutical-s-new-hypertension-drug-trials-approved-tipranks-com 2024-09-20T09:16:05+00:00 weekly 0.7 https://trial.medpath.com/news/yoga-other-exercise-can-curb-urinary-incontinence-in-women 2024-09-20T09:09:50+00:00 weekly 0.7 https://trial.medpath.com/zh/news/yoga-other-exercise-can-curb-urinary-incontinence-in-women 2024-09-20T09:09:50+00:00 weekly 0.7 https://trial.medpath.com/news/are-antidepressants-being-overused-to-treat-seniors-pain 2024-09-20T09:09:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/are-antidepressants-being-overused-to-treat-seniors-pain 2024-09-20T09:09:24+00:00 weekly 0.7 https://trial.medpath.com/news/caring-for-horses-could-help-veterans-battling-ptsd 2024-09-20T09:09:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/caring-for-horses-could-help-veterans-battling-ptsd 2024-09-20T09:09:04+00:00 weekly 0.7 https://trial.medpath.com/news/dad-s-epilepsy-med-valproate-use-won-t-harm-his-kids-study 2024-09-20T09:09:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dad-s-epilepsy-med-valproate-use-won-t-harm-his-kids-study 2024-09-20T09:09:01+00:00 weekly 0.7 https://trial.medpath.com/news/european-ai-healthcare-startups-drive-medical-innovation-with-advanced-analytics-and-clinical-trial-solutions 2024-09-20T09:07:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/european-ai-healthcare-startups-drive-medical-innovation-with-advanced-analytics-and-clinical-trial-solutions 2024-09-20T09:07:48+00:00 weekly 0.7 https://trial.medpath.com/news/gc-therapeutics-raises-65m-to-accelerate-revolutionary-ipsc-cell-programming-platform 2024-09-20T08:42:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gc-therapeutics-raises-65m-to-accelerate-revolutionary-ipsc-cell-programming-platform 2024-09-20T08:42:38+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-to-launch-palivizumab-synagis-in-india-express-pharma 2024-09-20T08:04:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-to-launch-palivizumab-synagis-in-india-express-pharma 2024-09-20T08:04:39+00:00 weekly 0.7 https://trial.medpath.com/news/recent-breakthroughs-in-cancer-research-could-impact-these-key-companies 2024-09-20T07:50:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/recent-breakthroughs-in-cancer-research-could-impact-these-key-companies 2024-09-20T07:50:57+00:00 weekly 0.7 https://trial.medpath.com/news/ai-language-model-achieves-87-accuracy-in-distinguishing-fibromyalgia-from-other-chronic-pain-conditions 2024-09-20T07:00:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-language-model-achieves-87-accuracy-in-distinguishing-fibromyalgia-from-other-chronic-pain-conditions 2024-09-20T07:00:01+00:00 weekly 0.7 https://trial.medpath.com/news/acelyrin-inc-announces-positive-results-from-global-phase-3-clinical-trial-of-izokibep 2024-09-20T06:42:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/acelyrin-inc-announces-positive-results-from-global-phase-3-clinical-trial-of-izokibep 2024-09-20T06:42:01+00:00 weekly 0.7 https://trial.medpath.com/news/new-treatment-strategies-emerge-for-managing-car-t-cell-therapy-side-effects 2024-09-20T05:55:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-treatment-strategies-emerge-for-managing-car-t-cell-therapy-side-effects 2024-09-20T05:55:07+00:00 weekly 0.7 https://trial.medpath.com/news/wockhardt-targets-global-launch-of-new-meningitis-drug-with-6-bn-market-potential-by-2026 2024-09-20T05:38:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/wockhardt-targets-global-launch-of-new-meningitis-drug-with-6-bn-market-potential-by-2026 2024-09-20T05:38:53+00:00 weekly 0.7 https://trial.medpath.com/news/dr-paulo-fontoura-md-phd-joins-stalicla-as-chief-scientific-and-clinical-development-advisor 2024-09-20T05:10:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-paulo-fontoura-md-phd-joins-stalicla-as-chief-scientific-and-clinical-development-advisor 2024-09-20T05:10:36+00:00 weekly 0.7 https://trial.medpath.com/news/hemophilia-b-clinical-trials-2024-ema-pdma-fda-approvals-openpr-com 2024-09-20T04:09:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hemophilia-b-clinical-trials-2024-ema-pdma-fda-approvals-openpr-com 2024-09-20T04:09:00+00:00 weekly 0.7 https://trial.medpath.com/news/adrenoleukodystrophy-clinical-trials-2024-ema-pdma-fda-openpr-com 2024-09-20T03:34:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/adrenoleukodystrophy-clinical-trials-2024-ema-pdma-fda-openpr-com 2024-09-20T03:34:01+00:00 weekly 0.7 https://trial.medpath.com/news/hitting-psoriatic-arthritis-early-with-apremilast-helps-some-patients-trial-finds 2024-09-20T03:13:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/hitting-psoriatic-arthritis-early-with-apremilast-helps-some-patients-trial-finds 2024-09-20T03:13:19+00:00 weekly 0.7 https://trial.medpath.com/news/mesoblast-meso-biotechnology-innovator-nearing-critical-milestones-for-life-changing-therapies 2024-09-20T03:07:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mesoblast-meso-biotechnology-innovator-nearing-critical-milestones-for-life-changing-therapies 2024-09-20T03:07:01+00:00 weekly 0.7 https://trial.medpath.com/news/pelareorep-plus-paclitaxel-extends-survival-in-hr-her2-breast-cancer 2024-09-20T02:26:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pelareorep-plus-paclitaxel-extends-survival-in-hr-her2-breast-cancer 2024-09-20T02:26:16+00:00 weekly 0.7 https://trial.medpath.com/news/study-reveals-biomarkers-that-predict-disability-worsening-in-multiple-sclerosis 2024-09-20T02:23:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-reveals-biomarkers-that-predict-disability-worsening-in-multiple-sclerosis 2024-09-20T02:23:25+00:00 weekly 0.7 https://trial.medpath.com/news/euro-roundup-ema-finalizes-reflection-paper-on-establishing-efficacy-based-on-single-arm-trials 2024-09-20T01:44:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/euro-roundup-ema-finalizes-reflection-paper-on-establishing-efficacy-based-on-single-arm-trials 2024-09-20T01:44:59+00:00 weekly 0.7 https://trial.medpath.com/news/roche-reports-positive-data-from-phase-iii-influenza-treatment-trial 2024-09-20T01:42:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/roche-reports-positive-data-from-phase-iii-influenza-treatment-trial 2024-09-20T01:42:57+00:00 weekly 0.7 https://trial.medpath.com/news/five-strategic-travel-solutions-to-boost-clinical-trial-diversity-and-patient-enrollment 2024-09-20T01:34:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/five-strategic-travel-solutions-to-boost-clinical-trial-diversity-and-patient-enrollment 2024-09-20T01:34:46+00:00 weekly 0.7 https://trial.medpath.com/news/rice-and-baylor-receive-2-8-million-to-suppress-inflammation-and-lung-damage 2024-09-20T00:19:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rice-and-baylor-receive-2-8-million-to-suppress-inflammation-and-lung-damage 2024-09-20T00:19:33+00:00 weekly 0.7 https://trial.medpath.com/news/checkmate-9er-post-hoc-analysis-seeks-to-identify-efficacy-biomarkers-for-nivolumab-onclive 2024-09-20T00:08:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/checkmate-9er-post-hoc-analysis-seeks-to-identify-efficacy-biomarkers-for-nivolumab-onclive 2024-09-20T00:08:22+00:00 weekly 0.7 https://trial.medpath.com/news/immix-biopharma-stock-hits-52-week-low-at-1-74-amid-market-challenges-by-investing-com 2024-09-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immix-biopharma-stock-hits-52-week-low-at-1-74-amid-market-challenges-by-investing-com 2024-09-20T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/kiromic-biopharma-activates-the-university-of-arizona-cancer-center-as-the-fifth-clinical 2024-09-19T23:27:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kiromic-biopharma-activates-the-university-of-arizona-cancer-center-as-the-fifth-clinical 2024-09-19T23:27:34+00:00 weekly 0.7 https://trial.medpath.com/news/beacon-therapeutics-presents-36-month-interim-results-from-phase-i-2-horizon-trial-biospace 2024-09-19T23:27:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/beacon-therapeutics-presents-36-month-interim-results-from-phase-i-2-horizon-trial-biospace 2024-09-19T23:27:32+00:00 weekly 0.7 https://trial.medpath.com/news/shaping-personalized-genetic-care-in-bc-ubc-faculty-of-medicine 2024-09-19T23:21:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/shaping-personalized-genetic-care-in-bc-ubc-faculty-of-medicine 2024-09-19T23:21:55+00:00 weekly 0.7 https://trial.medpath.com/news/fda-fast-track-designation-for-narmafotinib-in-advanced-pancreatic-cancer 2024-09-19T23:14:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-fast-track-designation-for-narmafotinib-in-advanced-pancreatic-cancer 2024-09-19T23:14:25+00:00 weekly 0.7 https://trial.medpath.com/news/asu-biochemist-honored-for-lifetime-achievement-in-improving-human-health 2024-09-19T22:17:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/asu-biochemist-honored-for-lifetime-achievement-in-improving-human-health 2024-09-19T22:17:12+00:00 weekly 0.7 https://trial.medpath.com/news/angiodynamics-initiates-recover-av-clinical-trial-assessing-alphavac-f1885-system-in 2024-09-19T22:15:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/angiodynamics-initiates-recover-av-clinical-trial-assessing-alphavac-f1885-system-in 2024-09-19T22:15:35+00:00 weekly 0.7 https://trial.medpath.com/news/mantle-cell-lymphoma-clinical-trial-pipeline-insights-featuring-20-companies-delveinsight 2024-09-19T21:53:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mantle-cell-lymphoma-clinical-trial-pipeline-insights-featuring-20-companies-delveinsight 2024-09-19T21:53:03+00:00 weekly 0.7 https://trial.medpath.com/news/cybin-provides-corporate-update-on-upcoming-clinical-milestones-morningstar 2024-09-19T21:50:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cybin-provides-corporate-update-on-upcoming-clinical-milestones-morningstar 2024-09-19T21:50:05+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-epitomee-an-ingestible-device-for-weight-management-neurology-advisor 2024-09-19T21:47:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-clears-epitomee-an-ingestible-device-for-weight-management-neurology-advisor 2024-09-19T21:47:28+00:00 weekly 0.7 https://trial.medpath.com/news/genfit-reports-first-half-year-2024-financial-results-and-provides-corporate-update 2024-09-19T21:28:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/genfit-reports-first-half-year-2024-financial-results-and-provides-corporate-update 2024-09-19T21:28:47+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-2024-research-roundup-cancer-therapy-advisor 2024-09-19T21:10:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/esmo-2024-research-roundup-cancer-therapy-advisor 2024-09-19T21:10:37+00:00 weekly 0.7 https://trial.medpath.com/news/earlier-info-on-financial-stress-obesity-and-second-cancers-carcinogenic-condoms 2024-09-19T21:09:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/earlier-info-on-financial-stress-obesity-and-second-cancers-carcinogenic-condoms 2024-09-19T21:09:30+00:00 weekly 0.7 https://trial.medpath.com/news/regulatory-actions-for-sept-19-2024-bioworld 2024-09-19T20:48:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/regulatory-actions-for-sept-19-2024-bioworld 2024-09-19T20:48:13+00:00 weekly 0.7 https://trial.medpath.com/news/rezolute-reports-fourth-quarter-and-full-year-fiscal-2024-financial-results-and-provides 2024-09-19T20:14:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rezolute-reports-fourth-quarter-and-full-year-fiscal-2024-financial-results-and-provides 2024-09-19T20:14:06+00:00 weekly 0.7 https://trial.medpath.com/news/rogaratinib-plus-atezolizumab-in-cisplatin-ineligible-patients-with-fgfr-rna-jama-network 2024-09-19T20:03:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rogaratinib-plus-atezolizumab-in-cisplatin-ineligible-patients-with-fgfr-rna-jama-network 2024-09-19T20:03:23+00:00 weekly 0.7 https://trial.medpath.com/news/novo-nordisk-a-s-wegovy-r-recommended-by-the-european-regulatory-authorities-for-label 2024-09-19T19:52:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novo-nordisk-a-s-wegovy-r-recommended-by-the-european-regulatory-authorities-for-label 2024-09-19T19:52:51+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-new-dosage-of-trastuzumab-biosimilar-for-her2-overexpressing-cancers 2024-09-19T19:31:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-new-dosage-of-trastuzumab-biosimilar-for-her2-overexpressing-cancers 2024-09-19T19:31:24+00:00 weekly 0.7 https://trial.medpath.com/news/elanco-announces-fda-approval-and-launch-of-zenreliatm-ilunocitinib-tablets-offering-an 2024-09-19T19:21:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/elanco-announces-fda-approval-and-launch-of-zenreliatm-ilunocitinib-tablets-offering-an 2024-09-19T19:21:32+00:00 weekly 0.7 https://trial.medpath.com/news/aplt-stock-soars-69-on-positive-update-on-galactosemia-drug-nda-yahoo-finance 2024-09-19T19:06:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aplt-stock-soars-69-on-positive-update-on-galactosemia-drug-nda-yahoo-finance 2024-09-19T19:06:32+00:00 weekly 0.7 https://trial.medpath.com/news/top-in-women-s-health-fda-warning-for-fezolinetant-trauma-may-be-toxic-for-brain-health 2024-09-19T18:55:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/top-in-women-s-health-fda-warning-for-fezolinetant-trauma-may-be-toxic-for-brain-health 2024-09-19T18:55:25+00:00 weekly 0.7 https://trial.medpath.com/news/bright-minds-biosciences-to-host-investor-analyst-kol-event-on-september-25th 2024-09-19T18:48:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bright-minds-biosciences-to-host-investor-analyst-kol-event-on-september-25th 2024-09-19T18:48:41+00:00 weekly 0.7 https://trial.medpath.com/news/recon-fda-rejects-vanda-s-stomach-condition-drug-eu-authorizes-bavarian-mpox-vaccine 2024-09-19T18:47:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/recon-fda-rejects-vanda-s-stomach-condition-drug-eu-authorizes-bavarian-mpox-vaccine 2024-09-19T18:47:53+00:00 weekly 0.7 https://trial.medpath.com/news/dr-srinivas-on-the-role-of-lutetium-lu-177-vipivotide-tetraxetan-in-mcrpc-onclive 2024-09-19T18:46:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-srinivas-on-the-role-of-lutetium-lu-177-vipivotide-tetraxetan-in-mcrpc-onclive 2024-09-19T18:46:03+00:00 weekly 0.7 https://trial.medpath.com/news/imvanex-opinion-on-variation-to-marketing-authorisation-european-medicines-agency 2024-09-19T18:43:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/imvanex-opinion-on-variation-to-marketing-authorisation-european-medicines-agency 2024-09-19T18:43:41+00:00 weekly 0.7 https://trial.medpath.com/news/summit-therapeutics-bests-merck-s-top-selling-drug-in-phase-iii-trial-seeking-alpha 2024-09-19T18:40:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/summit-therapeutics-bests-merck-s-top-selling-drug-in-phase-iii-trial-seeking-alpha 2024-09-19T18:40:04+00:00 weekly 0.7 https://trial.medpath.com/news/arterial-hypertension-clinical-trials-update-2024-nature 2024-09-19T18:25:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/arterial-hypertension-clinical-trials-update-2024-nature 2024-09-19T18:25:36+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trial-could-move-the-needle-in-traumatic-brain-injury-uc-san-francisco 2024-09-19T18:02:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trial-could-move-the-needle-in-traumatic-brain-injury-uc-san-francisco 2024-09-19T18:02:01+00:00 weekly 0.7 https://trial.medpath.com/news/rintatolimod-plus-durvalumab-shows-early-disease-control-in-late-stage-pancreatic-cancer 2024-09-19T17:43:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rintatolimod-plus-durvalumab-shows-early-disease-control-in-late-stage-pancreatic-cancer 2024-09-19T17:43:24+00:00 weekly 0.7 https://trial.medpath.com/news/unlv-and-global-alzheimer-s-organization-collaborating-to-bring-next-gen-research-to-las-vegas 2024-09-19T16:30:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/unlv-and-global-alzheimer-s-organization-collaborating-to-bring-next-gen-research-to-las-vegas 2024-09-19T16:30:56+00:00 weekly 0.7 https://trial.medpath.com/news/rapid-normalization-of-vitamin-d-deficiency-in-picu-vitdalize-kids-trials-journal 2024-09-19T15:37:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rapid-normalization-of-vitamin-d-deficiency-in-picu-vitdalize-kids-trials-journal 2024-09-19T15:37:45+00:00 weekly 0.7 https://trial.medpath.com/news/phase-2-remark-trial-of-rvu120-doses-first-patient-with-lower-risk-mds 2024-09-19T15:33:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-2-remark-trial-of-rvu120-doses-first-patient-with-lower-risk-mds 2024-09-19T15:33:10+00:00 weekly 0.7 https://trial.medpath.com/news/ema-recommends-extending-indication-of-mpox-vaccine-to-adolescents 2024-09-19T15:29:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ema-recommends-extending-indication-of-mpox-vaccine-to-adolescents 2024-09-19T15:29:10+00:00 weekly 0.7 https://trial.medpath.com/news/certain-diabetes-drugs-may-lower-risk-of-dementia-and-parkinson-s-disease 2024-09-19T15:23:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/certain-diabetes-drugs-may-lower-risk-of-dementia-and-parkinson-s-disease 2024-09-19T15:23:42+00:00 weekly 0.7 https://trial.medpath.com/news/pharmacosmos-completes-strategic-acquisition-of-g1-therapeutics-in-multi-million-dollar-deal 2024-09-19T15:21:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharmacosmos-completes-strategic-acquisition-of-g1-therapeutics-in-multi-million-dollar-deal 2024-09-19T15:21:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-declines-to-approve-vanda-s-marketing-application-for-tradipitant-in-gastroparesis 2024-09-19T15:18:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-declines-to-approve-vanda-s-marketing-application-for-tradipitant-in-gastroparesis 2024-09-19T15:18:19+00:00 weekly 0.7 https://trial.medpath.com/news/mpox-three-ongoing-vaccine-trials-to-watch-clinical-trials-arena 2024-09-19T15:16:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mpox-three-ongoing-vaccine-trials-to-watch-clinical-trials-arena 2024-09-19T15:16:08+00:00 weekly 0.7 https://trial.medpath.com/news/trial-supports-uninterrupted-use-of-imatinib-for-gist-nci 2024-09-19T15:15:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/trial-supports-uninterrupted-use-of-imatinib-for-gist-nci 2024-09-19T15:15:51+00:00 weekly 0.7 https://trial.medpath.com/news/comparative-effects-of-drug-interventions-for-the-acute-management-of-migraine-episodes-in-adults 2024-09-19T15:14:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/comparative-effects-of-drug-interventions-for-the-acute-management-of-migraine-episodes-in-adults 2024-09-19T15:14:09+00:00 weekly 0.7 https://trial.medpath.com/news/overall-survival-with-cabozantinib-vs-sunitinib-in-advanced-papillary-renal-cell-carcinoma 2024-09-19T15:09:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/overall-survival-with-cabozantinib-vs-sunitinib-in-advanced-papillary-renal-cell-carcinoma 2024-09-19T15:09:35+00:00 weekly 0.7 https://trial.medpath.com/news/chip-and-mcas-linked-to-risk-of-cancer-death-hematology-advisor 2024-09-19T15:01:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chip-and-mcas-linked-to-risk-of-cancer-death-hematology-advisor 2024-09-19T15:01:52+00:00 weekly 0.7 https://trial.medpath.com/news/university-of-hong-kong-opens-first-clinical-trials-centre-with-private-hospital-cancer-a-focus 2024-09-19T15:00:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/university-of-hong-kong-opens-first-clinical-trials-centre-with-private-hospital-cancer-a-focus 2024-09-19T15:00:11+00:00 weekly 0.7 https://trial.medpath.com/news/immunotherapy-clinical-trials-a-new-approach-to-treating-cancer-yahoo-finance 2024-09-19T14:37:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immunotherapy-clinical-trials-a-new-approach-to-treating-cancer-yahoo-finance 2024-09-19T14:37:32+00:00 weekly 0.7 https://trial.medpath.com/news/non-invasive-method-can-help-predict-survival-in-patients-with-liver-cancer-medical-xpress 2024-09-19T14:32:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/non-invasive-method-can-help-predict-survival-in-patients-with-liver-cancer-medical-xpress 2024-09-19T14:32:17+00:00 weekly 0.7 https://trial.medpath.com/news/bavarian-nordic-gets-ema-approval-of-mpox-vaccine-for-adolescents-proinvestor 2024-09-19T14:22:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bavarian-nordic-gets-ema-approval-of-mpox-vaccine-for-adolescents-proinvestor 2024-09-19T14:22:34+00:00 weekly 0.7 https://trial.medpath.com/news/22q11-2-deletion-syndrome-pipeline-market-research-report-2024-yahoo-finance 2024-09-19T14:19:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/22q11-2-deletion-syndrome-pipeline-market-research-report-2024-yahoo-finance 2024-09-19T14:19:51+00:00 weekly 0.7 https://trial.medpath.com/news/imac-holdings-inc-launches-subsidiary-ignite-proteomics-and-announces-groundbreaking 2024-09-19T14:10:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/imac-holdings-inc-launches-subsidiary-ignite-proteomics-and-announces-groundbreaking 2024-09-19T14:10:14+00:00 weekly 0.7 https://trial.medpath.com/news/anticipated-cancer-antibody-drug-conjugates-fda-approval-by-2027-biospace 2024-09-19T13:52:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/anticipated-cancer-antibody-drug-conjugates-fda-approval-by-2027-biospace 2024-09-19T13:52:43+00:00 weekly 0.7 https://trial.medpath.com/news/traveler-s-diarrhea-therapeutics-pipeline-market-report-2024-featuring-immuron 2024-09-19T13:49:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/traveler-s-diarrhea-therapeutics-pipeline-market-report-2024-featuring-immuron 2024-09-19T13:49:20+00:00 weekly 0.7 https://trial.medpath.com/news/starton-successfully-delivers-cancer-drug-using-on-body-injector-clinical-trials-arena 2024-09-19T13:44:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/starton-successfully-delivers-cancer-drug-using-on-body-injector-clinical-trials-arena 2024-09-19T13:44:44+00:00 weekly 0.7 https://trial.medpath.com/news/newron-presents-h1-2024-results-and-provides-business-update-morningstar 2024-09-19T13:30:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/newron-presents-h1-2024-results-and-provides-business-update-morningstar 2024-09-19T13:30:01+00:00 weekly 0.7 https://trial.medpath.com/news/mda-awards-500000-grant-to-accelerate-als-research-globenewswire 2024-09-19T13:25:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mda-awards-500000-grant-to-accelerate-als-research-globenewswire 2024-09-19T13:25:02+00:00 weekly 0.7 https://trial.medpath.com/news/apnimed-announces-early-completion-of-enrollment-in-phase-3-synairgy-study-of-ad109 2024-09-19T13:16:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/apnimed-announces-early-completion-of-enrollment-in-phase-3-synairgy-study-of-ad109 2024-09-19T13:16:58+00:00 weekly 0.7 https://trial.medpath.com/news/covid-may-trigger-chronic-fatigue-syndrome-kaiser-permanente-division-of-research 2024-09-19T13:08:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/covid-may-trigger-chronic-fatigue-syndrome-kaiser-permanente-division-of-research 2024-09-19T13:08:19+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-announces-start-of-recruitment-in-two-new-phase-iii-trials-evaluating-saphnelo 2024-09-19T13:07:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-announces-start-of-recruitment-in-two-new-phase-iii-trials-evaluating-saphnelo 2024-09-19T13:07:58+00:00 weekly 0.7 https://trial.medpath.com/news/pharmacogenomics-pioneer-to-lead-first-multinational-study-university-world-news 2024-09-19T13:07:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharmacogenomics-pioneer-to-lead-first-multinational-study-university-world-news 2024-09-19T13:07:27+00:00 weekly 0.7 https://trial.medpath.com/news/edgewise-therapeutics-announces-positive-top-line-data-from-phase-1-trial-in-healthy 2024-09-19T12:50:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/edgewise-therapeutics-announces-positive-top-line-data-from-phase-1-trial-in-healthy 2024-09-19T12:50:25+00:00 weekly 0.7 https://trial.medpath.com/news/biosyngen-presents-pioneering-conditional-activation-armor-enhancement-super-t 2024-09-19T12:47:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biosyngen-presents-pioneering-conditional-activation-armor-enhancement-super-t 2024-09-19T12:47:24+00:00 weekly 0.7 https://trial.medpath.com/news/longboard-pharmaceuticals-receives-rare-pediatric-disease-designation-and-stock-titan 2024-09-19T12:39:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/longboard-pharmaceuticals-receives-rare-pediatric-disease-designation-and-stock-titan 2024-09-19T12:39:06+00:00 weekly 0.7 https://trial.medpath.com/news/oric-pharmaceuticals-maintains-buy-rating-amidst-competitive-landscape 2024-09-19T12:23:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oric-pharmaceuticals-maintains-buy-rating-amidst-competitive-landscape 2024-09-19T12:23:07+00:00 weekly 0.7 https://trial.medpath.com/news/novel-ar-degraders-and-emerging-therapies-show-promise-in-advanced-prostate-cancer-treatment 2024-09-19T12:22:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-ar-degraders-and-emerging-therapies-show-promise-in-advanced-prostate-cancer-treatment 2024-09-19T12:22:27+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-builds-combo-case-for-rsv-shingles-shots-with-phase-iii-data-biospace 2024-09-19T12:11:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gsk-builds-combo-case-for-rsv-shingles-shots-with-phase-iii-data-biospace 2024-09-19T12:11:58+00:00 weekly 0.7 https://trial.medpath.com/news/takeda-to-present-additional-clinical-trial-study-data-highlighting-the-impact-of-orexin 2024-09-19T12:06:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/takeda-to-present-additional-clinical-trial-study-data-highlighting-the-impact-of-orexin 2024-09-19T12:06:36+00:00 weekly 0.7 https://trial.medpath.com/news/kiromic-biopharma-advances-deltacel-01-into-expansion-phase-following-safety 2024-09-19T12:05:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kiromic-biopharma-advances-deltacel-01-into-expansion-phase-following-safety 2024-09-19T12:05:24+00:00 weekly 0.7 https://trial.medpath.com/news/quralis-announces-expansion-of-its-selective-kv7-2-7-3-ion-channel-opener-qrl-101-into-epilepsy 2024-09-19T11:48:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/quralis-announces-expansion-of-its-selective-kv7-2-7-3-ion-channel-opener-qrl-101-into-epilepsy 2024-09-19T11:48:08+00:00 weekly 0.7 https://trial.medpath.com/news/skb264-innovative-cancer-antibody-drug-conjugate-clinical-trials-efficacy-insight 2024-09-19T11:47:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/skb264-innovative-cancer-antibody-drug-conjugate-clinical-trials-efficacy-insight 2024-09-19T11:47:02+00:00 weekly 0.7 https://trial.medpath.com/news/phase-3-study-shows-viability-of-177lu-psma-617-for-taxane-naive-metastatic-castration 2024-09-19T11:21:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-3-study-shows-viability-of-177lu-psma-617-for-taxane-naive-metastatic-castration 2024-09-19T11:21:06+00:00 weekly 0.7 https://trial.medpath.com/news/xspray-pharma-announces-positive-fda-meeting-and-plans-for-dasynoc-nda-resubmission 2024-09-19T11:16:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/xspray-pharma-announces-positive-fda-meeting-and-plans-for-dasynoc-nda-resubmission 2024-09-19T11:16:42+00:00 weekly 0.7 https://trial.medpath.com/news/irinotecan-hydrochloride-liposome-hr070803-in-combination-with-5-fluorouracil-and-nature 2024-09-19T11:07:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/irinotecan-hydrochloride-liposome-hr070803-in-combination-with-5-fluorouracil-and-nature 2024-09-19T11:07:57+00:00 weekly 0.7 https://trial.medpath.com/news/trastuzumab-biosimilar-and-pertuzumab-effective-safe-in-neoadjuvant-breast-cancer-therapy 2024-09-19T11:06:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/trastuzumab-biosimilar-and-pertuzumab-effective-safe-in-neoadjuvant-breast-cancer-therapy 2024-09-19T11:06:26+00:00 weekly 0.7 https://trial.medpath.com/news/carematrix-launches-blinded-remote-monitoring-tech-for-clinical-trials 2024-09-19T10:35:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/carematrix-launches-blinded-remote-monitoring-tech-for-clinical-trials 2024-09-19T10:35:32+00:00 weekly 0.7 https://trial.medpath.com/news/nurabio-closes-140m-fundraising-to-develop-neuroprotective-drugs 2024-09-19T10:33:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nurabio-closes-140m-fundraising-to-develop-neuroprotective-drugs 2024-09-19T10:33:47+00:00 weekly 0.7 https://trial.medpath.com/news/lecanemab-s-benefits-are-too-small-and-uncertain-the-bmj 2024-09-19T09:54:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lecanemab-s-benefits-are-too-small-and-uncertain-the-bmj 2024-09-19T09:54:51+00:00 weekly 0.7 https://trial.medpath.com/news/bayer-s-nubeqa-breakthrough-in-prostate-cancer-with-46-risk-reduction-and-future 2024-09-19T09:50:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bayer-s-nubeqa-breakthrough-in-prostate-cancer-with-46-risk-reduction-and-future 2024-09-19T09:50:43+00:00 weekly 0.7 https://trial.medpath.com/news/elacestrant-plus-abemaciclib-demonstrates-clinical-benefit-in-pretreated-er-her2-onclive 2024-09-19T09:45:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/elacestrant-plus-abemaciclib-demonstrates-clinical-benefit-in-pretreated-er-her2-onclive 2024-09-19T09:45:24+00:00 weekly 0.7 https://trial.medpath.com/news/effectiveness-of-long-term-low-dose-aspirin-in-the-prevention-of-gastric-cancer-after 2024-09-19T09:42:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/effectiveness-of-long-term-low-dose-aspirin-in-the-prevention-of-gastric-cancer-after 2024-09-19T09:42:24+00:00 weekly 0.7 https://trial.medpath.com/news/we-are-funding-hope-montreal-children-s-hospital-gets-a-boost-for-cancer-clinical-trials 2024-09-19T09:25:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/we-are-funding-hope-montreal-children-s-hospital-gets-a-boost-for-cancer-clinical-trials 2024-09-19T09:25:22+00:00 weekly 0.7 https://trial.medpath.com/news/biopharma-services-announces-expansion-into-late-stage-patient-trials-and-integration 2024-09-19T07:30:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biopharma-services-announces-expansion-into-late-stage-patient-trials-and-integration 2024-09-19T07:30:53+00:00 weekly 0.7 https://trial.medpath.com/news/global-superbug-crisis-amr-deaths-projected-to-reach-39-million-by-2050-lancet-study-warns 2024-09-19T07:01:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/global-superbug-crisis-amr-deaths-projected-to-reach-39-million-by-2050-lancet-study-warns 2024-09-19T07:01:20+00:00 weekly 0.7 https://trial.medpath.com/news/positive-pre-clinical-result-drive-to-human-trials-company-announcement-investegate 2024-09-19T06:03:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/positive-pre-clinical-result-drive-to-human-trials-company-announcement-investegate 2024-09-19T06:03:28+00:00 weekly 0.7 https://trial.medpath.com/news/egetis-submits-a-patent-application-to-the-united-states-patent-and-trademark-office-for 2024-09-19T05:12:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/egetis-submits-a-patent-application-to-the-united-states-patent-and-trademark-office-for 2024-09-19T05:12:06+00:00 weekly 0.7 https://trial.medpath.com/news/flatiron-health-expands-its-mission-to-make-trials-more-pragmatic 2024-09-19T05:00:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/flatiron-health-expands-its-mission-to-make-trials-more-pragmatic 2024-09-19T05:00:04+00:00 weekly 0.7 https://trial.medpath.com/news/lupin-partners-with-takeda-to-launch-novel-acid-blocker-vonoprazan-in-india 2024-09-19T02:21:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lupin-partners-with-takeda-to-launch-novel-acid-blocker-vonoprazan-in-india 2024-09-19T02:21:05+00:00 weekly 0.7 https://trial.medpath.com/news/three-major-trends-reshaping-precision-medicine-ai-crispr-and-mrna-technologies-lead-innovation 2024-09-19T00:39:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/three-major-trends-reshaping-precision-medicine-ai-crispr-and-mrna-technologies-lead-innovation 2024-09-19T00:39:05+00:00 weekly 0.7 https://trial.medpath.com/news/transcenta-updates-encouraging-efficacy-data-from-first-line-triple-combo-trial-of-pr-newswire 2024-09-19T00:11:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/transcenta-updates-encouraging-efficacy-data-from-first-line-triple-combo-trial-of-pr-newswire 2024-09-19T00:11:33+00:00 weekly 0.7 https://trial.medpath.com/news/clinical-trials-at-sidra-medicine-offers-hope-to-children-with-rare-diseases 2024-09-19T00:02:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/clinical-trials-at-sidra-medicine-offers-hope-to-children-with-rare-diseases 2024-09-19T00:02:19+00:00 weekly 0.7 https://trial.medpath.com/news/study-finds-no-short-term-benefit-of-adding-revascularization-to-medical-therapy-for-carotid-stenosis 2024-09-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-finds-no-short-term-benefit-of-adding-revascularization-to-medical-therapy-for-carotid-stenosis 2024-09-19T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/sprc-scisparc-ltd-ordinary-shares-latest-stock-news-market-updates 2024-09-18T23:54:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sprc-scisparc-ltd-ordinary-shares-latest-stock-news-market-updates 2024-09-18T23:54:58+00:00 weekly 0.7 https://trial.medpath.com/news/organon-gets-more-skin-in-the-game-by-acquiring-roivant-s-dermatology-subsidiary 2024-09-18T23:30:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/organon-gets-more-skin-in-the-game-by-acquiring-roivant-s-dermatology-subsidiary 2024-09-18T23:30:39+00:00 weekly 0.7 https://trial.medpath.com/news/reactivating-interest-in-hsv-shedding-after-solid-organ-transplant-fred-hutchinson-cancer-center 2024-09-18T22:50:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/reactivating-interest-in-hsv-shedding-after-solid-organ-transplant-fred-hutchinson-cancer-center 2024-09-18T22:50:04+00:00 weekly 0.7 https://trial.medpath.com/news/improving-car-t-cell-efficacy-via-new-manufacturing-process 2024-09-18T22:25:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/improving-car-t-cell-efficacy-via-new-manufacturing-process 2024-09-18T22:25:54+00:00 weekly 0.7 https://trial.medpath.com/news/applied-therapeutics-provides-regulatory-update-on-govorestat-for-the-treatment-of-classic-galactosemia 2024-09-18T22:11:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/applied-therapeutics-provides-regulatory-update-on-govorestat-for-the-treatment-of-classic-galactosemia 2024-09-18T22:11:44+00:00 weekly 0.7 https://trial.medpath.com/news/new-briumvi-r-ublituximab-xiiy-data-from-the-enhance-phase-3b-study-show-rapid-30 2024-09-18T21:57:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-briumvi-r-ublituximab-xiiy-data-from-the-enhance-phase-3b-study-show-rapid-30 2024-09-18T21:57:15+00:00 weekly 0.7 https://trial.medpath.com/news/applied-therapeutics-provides-regulatory-update-on-govorestat-for-the-treatment-of-biospace 2024-09-18T21:57:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/applied-therapeutics-provides-regulatory-update-on-govorestat-for-the-treatment-of-biospace 2024-09-18T21:57:11+00:00 weekly 0.7 https://trial.medpath.com/news/bone-marrow-cancer-drug-shows-success-in-treatment-of-rare-blood-disorder 2024-09-18T21:22:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bone-marrow-cancer-drug-shows-success-in-treatment-of-rare-blood-disorder 2024-09-18T21:22:58+00:00 weekly 0.7 https://trial.medpath.com/news/lenvatinib-combo-yields-substantial-antitumor-activity-in-endometrial-cancer 2024-09-18T21:11:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lenvatinib-combo-yields-substantial-antitumor-activity-in-endometrial-cancer 2024-09-18T21:11:38+00:00 weekly 0.7 https://trial.medpath.com/news/4dmt-shares-data-from-phase-1-2-prism-clinical-trial-4front-phase-3-study-design 2024-09-18T21:02:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/4dmt-shares-data-from-phase-1-2-prism-clinical-trial-4front-phase-3-study-design 2024-09-18T21:02:05+00:00 weekly 0.7 https://trial.medpath.com/news/addition-of-palliative-radiotherapy-to-best-supportive-care-in-painful-hepatic-cancer 2024-09-18T20:52:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/addition-of-palliative-radiotherapy-to-best-supportive-care-in-painful-hepatic-cancer 2024-09-18T20:52:41+00:00 weekly 0.7 https://trial.medpath.com/news/new-study-challenges-amyloid-beta-theory-on-cause-for-alzheimer-s-disease 2024-09-18T20:38:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-study-challenges-amyloid-beta-theory-on-cause-for-alzheimer-s-disease 2024-09-18T20:38:35+00:00 weekly 0.7 https://trial.medpath.com/news/park-and-patel-explore-advances-in-egfr-nsclc-from-asco-2024-onclive 2024-09-18T20:27:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/park-and-patel-explore-advances-in-egfr-nsclc-from-asco-2024-onclive 2024-09-18T20:27:40+00:00 weekly 0.7 https://trial.medpath.com/news/phelps-health-offers-inspire-therapy-for-obstructive-sleep-apnea-news-phelpscountyfocus-com 2024-09-18T20:26:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phelps-health-offers-inspire-therapy-for-obstructive-sleep-apnea-news-phelpscountyfocus-com 2024-09-18T20:26:13+00:00 weekly 0.7 https://trial.medpath.com/news/ossium-treats-first-leukaemia-patient-in-cryopreserved-bone-marrow-trial 2024-09-18T20:20:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ossium-treats-first-leukaemia-patient-in-cryopreserved-bone-marrow-trial 2024-09-18T20:20:28+00:00 weekly 0.7 https://trial.medpath.com/news/vivos-therapeutics-says-it-is-poised-to-disrupt-pediatric-sleep-apnea-market-secures-fda 2024-09-18T20:20:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vivos-therapeutics-says-it-is-poised-to-disrupt-pediatric-sleep-apnea-market-secures-fda 2024-09-18T20:20:04+00:00 weekly 0.7 https://trial.medpath.com/news/medicaid-might-help-increase-clinical-trial-diversity-penn-ldi 2024-09-18T20:18:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medicaid-might-help-increase-clinical-trial-diversity-penn-ldi 2024-09-18T20:18:11+00:00 weekly 0.7 https://trial.medpath.com/news/scisparc-takes-major-step-forward-with-ind-application-submitted-to-the-fda-for-phase-iib 2024-09-18T20:17:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/scisparc-takes-major-step-forward-with-ind-application-submitted-to-the-fda-for-phase-iib 2024-09-18T20:17:52+00:00 weekly 0.7 https://trial.medpath.com/news/fewer-cancer-drugs-exempt-from-pediatric-testing-after-race-act-healio 2024-09-18T20:10:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fewer-cancer-drugs-exempt-from-pediatric-testing-after-race-act-healio 2024-09-18T20:10:54+00:00 weekly 0.7 https://trial.medpath.com/news/exploring-advancements-in-higher-risk-mds-targeted-oncology 2024-09-18T20:03:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/exploring-advancements-in-higher-risk-mds-targeted-oncology 2024-09-18T20:03:13+00:00 weekly 0.7 https://trial.medpath.com/news/new-trial-to-test-potential-treatment-for-chronic-kidney-disease-university-of-oxford 2024-09-18T19:55:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-trial-to-test-potential-treatment-for-chronic-kidney-disease-university-of-oxford 2024-09-18T19:55:04+00:00 weekly 0.7 https://trial.medpath.com/news/personalized-treatment-could-be-key-to-tackling-uncontrolled-high-blood-pressure 2024-09-18T19:54:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/personalized-treatment-could-be-key-to-tackling-uncontrolled-high-blood-pressure 2024-09-18T19:54:04+00:00 weekly 0.7 https://trial.medpath.com/news/aclaris-doses-first-subject-in-phase-iia-atopic-dermatitis-treatment-trial 2024-09-18T19:37:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/aclaris-doses-first-subject-in-phase-iia-atopic-dermatitis-treatment-trial 2024-09-18T19:37:38+00:00 weekly 0.7 https://trial.medpath.com/news/implantica-s-anti-reflux-device-shows-positive-two-year-results-clinical-trials-arena 2024-09-18T19:37:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/implantica-s-anti-reflux-device-shows-positive-two-year-results-clinical-trials-arena 2024-09-18T19:37:38+00:00 weekly 0.7 https://trial.medpath.com/news/medical-breakthrough-new-drug-being-tested-to-help-treat-strokes-krgv 2024-09-18T19:09:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medical-breakthrough-new-drug-being-tested-to-help-treat-strokes-krgv 2024-09-18T19:09:29+00:00 weekly 0.7 https://trial.medpath.com/news/alteogen-seeks-approval-for-aflibercept-biosimilar-in-korea-goodwin-jdsupra 2024-09-18T18:38:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alteogen-seeks-approval-for-aflibercept-biosimilar-in-korea-goodwin-jdsupra 2024-09-18T18:38:15+00:00 weekly 0.7 https://trial.medpath.com/news/sunrise-4-neoadjuvant-tar-200-cetrelimab-is-linked-with-strong-pcr-por-in-mibc 2024-09-18T18:18:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sunrise-4-neoadjuvant-tar-200-cetrelimab-is-linked-with-strong-pcr-por-in-mibc 2024-09-18T18:18:11+00:00 weekly 0.7 https://trial.medpath.com/news/oral-geographic-atrophy-treatment-misses-primary-endpoint-in-phase-3-study-healio 2024-09-18T17:18:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/oral-geographic-atrophy-treatment-misses-primary-endpoint-in-phase-3-study-healio 2024-09-18T17:18:10+00:00 weekly 0.7 https://trial.medpath.com/news/plaquetec-and-rxcelerate-collaborate-on-early-phase-drug-discovery-for-coronary-artery-disease 2024-09-18T17:18:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/plaquetec-and-rxcelerate-collaborate-on-early-phase-drug-discovery-for-coronary-artery-disease 2024-09-18T17:18:01+00:00 weekly 0.7 https://trial.medpath.com/news/dr-toni-choueiri-on-key-takeaways-from-tinivo-2-trial-urology-times 2024-09-18T17:15:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-toni-choueiri-on-key-takeaways-from-tinivo-2-trial-urology-times 2024-09-18T17:15:27+00:00 weekly 0.7 https://trial.medpath.com/news/kesimpta-shows-promise-in-reducing-relapsing-multiple-sclerosis-disability-progression 2024-09-18T16:40:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kesimpta-shows-promise-in-reducing-relapsing-multiple-sclerosis-disability-progression 2024-09-18T16:40:27+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-orphan-drug-designation-to-cf33-hnis-for-cholangiocarcinoma-onclive 2024-09-18T16:34:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-orphan-drug-designation-to-cf33-hnis-for-cholangiocarcinoma-onclive 2024-09-18T16:34:07+00:00 weekly 0.7 https://trial.medpath.com/news/usc-launches-study-on-how-type-1-diabetes-affects-childhood-brain-development 2024-09-18T16:15:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/usc-launches-study-on-how-type-1-diabetes-affects-childhood-brain-development 2024-09-18T16:15:55+00:00 weekly 0.7 https://trial.medpath.com/news/nih-led-studies-point-to-potential-development-of-a-cataract-drug 2024-09-18T15:23:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nih-led-studies-point-to-potential-development-of-a-cataract-drug 2024-09-18T15:23:59+00:00 weekly 0.7 https://trial.medpath.com/news/io-therapeutics-inc-presented-data-from-studies-of-irx4204-the-company-s-phase-ii-morningstar 2024-09-18T15:17:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/io-therapeutics-inc-presented-data-from-studies-of-irx4204-the-company-s-phase-ii-morningstar 2024-09-18T15:17:18+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-data-show-durvalumab-improves-overall-survival-event-free-survival-pharmacy-times 2024-09-18T15:09:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/esmo-data-show-durvalumab-improves-overall-survival-event-free-survival-pharmacy-times 2024-09-18T15:09:08+00:00 weekly 0.7 https://trial.medpath.com/news/dato-dxd-demonstrates-efficacy-safety-in-platinum-resistant-ovarian-and-endometrial-cancers 2024-09-18T14:42:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dato-dxd-demonstrates-efficacy-safety-in-platinum-resistant-ovarian-and-endometrial-cancers 2024-09-18T14:42:30+00:00 weekly 0.7 https://trial.medpath.com/news/it-s-past-time-to-end-hiv-wonder-drug-experimentation-in-africa-stat-news 2024-09-18T14:33:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/it-s-past-time-to-end-hiv-wonder-drug-experimentation-in-africa-stat-news 2024-09-18T14:33:42+00:00 weekly 0.7 https://trial.medpath.com/news/kaida-biopharma-launches-social-media-channels-morningstar 2024-09-18T14:18:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/kaida-biopharma-launches-social-media-channels-morningstar 2024-09-18T14:18:29+00:00 weekly 0.7 https://trial.medpath.com/news/research-study-participants-are-more-engaged-when-they-see-their-test-results-uic-today 2024-09-18T14:06:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/research-study-participants-are-more-engaged-when-they-see-their-test-results-uic-today 2024-09-18T14:06:26+00:00 weekly 0.7 https://trial.medpath.com/news/glycomine-receives-fda-fast-track-designation-for-glm101-for-the-treatment-of-pmm2-cdg 2024-09-18T13:49:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/glycomine-receives-fda-fast-track-designation-for-glm101-for-the-treatment-of-pmm2-cdg 2024-09-18T13:49:02+00:00 weekly 0.7 https://trial.medpath.com/news/azitra-receives-fast-track-designation-for-atr-04-for-skin-rash-from-egfr-inhibitors 2024-09-18T13:37:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/azitra-receives-fast-track-designation-for-atr-04-for-skin-rash-from-egfr-inhibitors 2024-09-18T13:37:05+00:00 weekly 0.7 https://trial.medpath.com/news/medtronic-teases-positive-data-adaptive-deep-brain-stimulation-trial 2024-09-18T13:35:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medtronic-teases-positive-data-adaptive-deep-brain-stimulation-trial 2024-09-18T13:35:41+00:00 weekly 0.7 https://trial.medpath.com/news/fda-lifts-partial-clinical-hold-on-vigil-neuroscience-s-phase-i-vg-3927-trial 2024-09-18T13:35:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-lifts-partial-clinical-hold-on-vigil-neuroscience-s-phase-i-vg-3927-trial 2024-09-18T13:35:41+00:00 weekly 0.7 https://trial.medpath.com/news/insilico-medicine-reports-positive-phase-iia-results-for-ism001-055-a-novel-first-in-class 2024-09-18T13:30:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/insilico-medicine-reports-positive-phase-iia-results-for-ism001-055-a-novel-first-in-class 2024-09-18T13:30:27+00:00 weekly 0.7 https://trial.medpath.com/news/tap-into-the-a4-study-for-unprecedented-alzheimer-s-clinical-trial-data 2024-09-18T13:23:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tap-into-the-a4-study-for-unprecedented-alzheimer-s-clinical-trial-data 2024-09-18T13:23:47+00:00 weekly 0.7 https://trial.medpath.com/news/praxis-precision-s-relutrigine-reduces-seizures-in-rare-epileptic-disorders-in-phase-2-clinical-trials 2024-09-18T12:59:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/praxis-precision-s-relutrigine-reduces-seizures-in-rare-epileptic-disorders-in-phase-2-clinical-trials 2024-09-18T12:59:14+00:00 weekly 0.7 https://trial.medpath.com/news/novo-nordisk-starts-new-phase-iii-study-with-wegovy-successor-medwatch 2024-09-18T12:46:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novo-nordisk-starts-new-phase-iii-study-with-wegovy-successor-medwatch 2024-09-18T12:46:40+00:00 weekly 0.7 https://trial.medpath.com/news/plus-therapeutics-showcases-new-interim-respect-gbm-phase-2-trial-data-at-the-2024 2024-09-18T12:15:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/plus-therapeutics-showcases-new-interim-respect-gbm-phase-2-trial-data-at-the-2024 2024-09-18T12:15:01+00:00 weekly 0.7 https://trial.medpath.com/news/briacell-announces-fda-authorized-expanded-access-policy-for-metastatic-breast-cancer-patients 2024-09-18T12:09:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/briacell-announces-fda-authorized-expanded-access-policy-for-metastatic-breast-cancer-patients 2024-09-18T12:09:37+00:00 weekly 0.7 https://trial.medpath.com/news/new-data-to-be-presented-from-eftisarc-neo-phase-ii-globenewswire 2024-09-18T12:07:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-data-to-be-presented-from-eftisarc-neo-phase-ii-globenewswire 2024-09-18T12:07:40+00:00 weekly 0.7 https://trial.medpath.com/news/accord-biopharma-inc-announces-u-s-food-drug-administration-approval-of-420mg 2024-09-18T12:06:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/accord-biopharma-inc-announces-u-s-food-drug-administration-approval-of-420mg 2024-09-18T12:06:15+00:00 weekly 0.7 https://trial.medpath.com/news/biosyngen-s-first-in-class-car-t-asset-targeting-solid-tumors-has-entered-pivotal-phase-ii 2024-09-18T11:31:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biosyngen-s-first-in-class-car-t-asset-targeting-solid-tumors-has-entered-pivotal-phase-ii 2024-09-18T11:31:06+00:00 weekly 0.7 https://trial.medpath.com/news/mira-pharmaceuticals-advances-ketamir-2-development-following-phase-1-design 2024-09-18T11:25:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mira-pharmaceuticals-advances-ketamir-2-development-following-phase-1-design 2024-09-18T11:25:29+00:00 weekly 0.7 https://trial.medpath.com/news/satellos-announces-dosing-of-first-participant-in-phase-1-clinical-study-of-sat-3247 2024-09-18T11:22:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/satellos-announces-dosing-of-first-participant-in-phase-1-clinical-study-of-sat-3247 2024-09-18T11:22:22+00:00 weekly 0.7 https://trial.medpath.com/news/planned-for-a-marathon-but-it-turned-into-a-sprint-a-blog-by-tunde-oremule-ent-registrar 2024-09-18T11:14:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/planned-for-a-marathon-but-it-turned-into-a-sprint-a-blog-by-tunde-oremule-ent-registrar 2024-09-18T11:14:24+00:00 weekly 0.7 https://trial.medpath.com/news/alk-renal-cell-carcinoma-case-study-demonstrates-success-of-precision-medicine-approach 2024-09-18T11:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alk-renal-cell-carcinoma-case-study-demonstrates-success-of-precision-medicine-approach 2024-09-18T11:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/mannkind-announces-clearance-from-pmda-to-initiate-phase-3-clinical-trial-icon-1-biospace 2024-09-18T10:47:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mannkind-announces-clearance-from-pmda-to-initiate-phase-3-clinical-trial-icon-1-biospace 2024-09-18T10:47:41+00:00 weekly 0.7 https://trial.medpath.com/news/invion-s-inv043-candidate-demonstrates-positive-results-in-phase-ii-prostate-cancer-trial 2024-09-18T09:56:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/invion-s-inv043-candidate-demonstrates-positive-results-in-phase-ii-prostate-cancer-trial 2024-09-18T09:56:15+00:00 weekly 0.7 https://trial.medpath.com/news/most-promising-new-drugs-for-hidradenitis-suppurativa-with-raj-chovatiya-md-phd 2024-09-18T09:33:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/most-promising-new-drugs-for-hidradenitis-suppurativa-with-raj-chovatiya-md-phd 2024-09-18T09:33:28+00:00 weekly 0.7 https://trial.medpath.com/news/post-op-keytruda-boosts-bladder-cancer-outcomes 2024-09-18T09:09:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/post-op-keytruda-boosts-bladder-cancer-outcomes 2024-09-18T09:09:10+00:00 weekly 0.7 https://trial.medpath.com/news/imcheck-receives-fda-fast-track-designation-for-ict01-in-globenewswire 2024-09-18T09:02:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/imcheck-receives-fda-fast-track-designation-for-ict01-in-globenewswire 2024-09-18T09:02:59+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-therapy-could-improve-outcomes-for-nasal-and-paranasal-sinus-cancer 2024-09-18T09:02:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neoadjuvant-therapy-could-improve-outcomes-for-nasal-and-paranasal-sinus-cancer 2024-09-18T09:02:20+00:00 weekly 0.7 https://trial.medpath.com/news/merit-medical-touts-positive-six-month-data-from-wave-trial 2024-09-18T08:43:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/merit-medical-touts-positive-six-month-data-from-wave-trial 2024-09-18T08:43:49+00:00 weekly 0.7 https://trial.medpath.com/news/nicox-announces-approval-of-zerviate-in-china-biospace 2024-09-18T08:31:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nicox-announces-approval-of-zerviate-in-china-biospace 2024-09-18T08:31:13+00:00 weekly 0.7 https://trial.medpath.com/news/fasenra-egpa-us-fda-approval-astrazeneca-cision-news 2024-09-18T08:20:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fasenra-egpa-us-fda-approval-astrazeneca-cision-news 2024-09-18T08:20:55+00:00 weekly 0.7 https://trial.medpath.com/news/sensorion-reports-2024-first-half-results-and-highlights-recent-updates-yahoo-finance 2024-09-18T06:58:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sensorion-reports-2024-first-half-results-and-highlights-recent-updates-yahoo-finance 2024-09-18T06:58:36+00:00 weekly 0.7 https://trial.medpath.com/news/wclc-2024-study-reveals-multiple-hidden-burdens-of-lung-cancer-treatment-financial-time-and-sexual-health-impacts 2024-09-18T06:37:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/wclc-2024-study-reveals-multiple-hidden-burdens-of-lung-cancer-treatment-financial-time-and-sexual-health-impacts 2024-09-18T06:37:40+00:00 weekly 0.7 https://trial.medpath.com/news/poolbeg-pharma-patent-portfolio-significantly-strengthened-expanded 2024-09-18T06:35:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/poolbeg-pharma-patent-portfolio-significantly-strengthened-expanded 2024-09-18T06:35:53+00:00 weekly 0.7 https://trial.medpath.com/news/immunic-presents-key-vidofludimus-calcium-data-at-the-40th-congress-of-ectrims 2024-09-18T06:30:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immunic-presents-key-vidofludimus-calcium-data-at-the-40th-congress-of-ectrims 2024-09-18T06:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/brenus-pharma-raises-25-million-to-accelerate-clinical-trials-of-its-precision-cancer-vaccines 2024-09-18T06:29:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/brenus-pharma-raises-25-million-to-accelerate-clinical-trials-of-its-precision-cancer-vaccines 2024-09-18T06:29:04+00:00 weekly 0.7 https://trial.medpath.com/news/fda-formalizes-protocol-for-international-cancer-trials-stat-news 2024-09-18T06:04:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-formalizes-protocol-for-international-cancer-trials-stat-news 2024-09-18T06:04:25+00:00 weekly 0.7 https://trial.medpath.com/news/valneva-seeks-approval-to-expand-ixchiq-chikungunya-vaccine-use-to-adolescents-in 2024-09-18T05:39:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/valneva-seeks-approval-to-expand-ixchiq-chikungunya-vaccine-use-to-adolescents-in 2024-09-18T05:39:09+00:00 weekly 0.7 https://trial.medpath.com/news/baptist-health-achieves-52-reduction-in-high-risk-infusion-errors-through-system-wide-pump-standardization 2024-09-18T05:17:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/baptist-health-achieves-52-reduction-in-high-risk-infusion-errors-through-system-wide-pump-standardization 2024-09-18T05:17:49+00:00 weekly 0.7 https://trial.medpath.com/news/lymphedema-risk-no-higher-with-3-week-rt-regimen-in-early-breast-cancer 2024-09-18T04:03:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lymphedema-risk-no-higher-with-3-week-rt-regimen-in-early-breast-cancer 2024-09-18T04:03:40+00:00 weekly 0.7 https://trial.medpath.com/news/autobahn-therapeutics-starts-trial-of-abx-002-for-major-depressive-disorder-in-adults 2024-09-18T03:43:14+00:00 weekly 0.7 https://trial.medpath.com/zh/news/autobahn-therapeutics-starts-trial-of-abx-002-for-major-depressive-disorder-in-adults 2024-09-18T03:43:14+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-nyse-lly-gains-fda-approval-for-ebglyss-expands-strategic-alliances-for 2024-09-18T02:08:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eli-lilly-nyse-lly-gains-fda-approval-for-ebglyss-expands-strategic-alliances-for 2024-09-18T02:08:49+00:00 weekly 0.7 https://trial.medpath.com/news/perioperative-durvalumab-reduced-risk-of-recurrence-or-death-vs-neoadjuvant-the-asco-post 2024-09-18T01:58:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/perioperative-durvalumab-reduced-risk-of-recurrence-or-death-vs-neoadjuvant-the-asco-post 2024-09-18T01:58:55+00:00 weekly 0.7 https://trial.medpath.com/news/breakthrough-in-long-covid-an-investigator-initiated-trial-iit-with-hyundai-bioscience-s 2024-09-18T01:41:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/breakthrough-in-long-covid-an-investigator-initiated-trial-iit-with-hyundai-bioscience-s 2024-09-18T01:41:01+00:00 weekly 0.7 https://trial.medpath.com/news/novel-triplet-regimen-yields-promising-response-in-advanced-phase-chronic-myeloid-leukemia 2024-09-18T00:49:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novel-triplet-regimen-yields-promising-response-in-advanced-phase-chronic-myeloid-leukemia 2024-09-18T00:49:24+00:00 weekly 0.7 https://trial.medpath.com/news/fda-considers-revoking-pfizer-covid-19-vaccine-authorization-for-healthy-children-under-5 2024-09-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-considers-revoking-pfizer-covid-19-vaccine-authorization-for-healthy-children-under-5 2024-09-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/bristol-myers-squibb-initiates-two-phase-i-trials-testing-novel-therapies-for-advanced-solid-tumors-and-relapsed-refractory-lymphomas 2024-09-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bristol-myers-squibb-initiates-two-phase-i-trials-testing-novel-therapies-for-advanced-solid-tumors-and-relapsed-refractory-lymphomas 2024-09-18T00:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/upfrontpsma-177lu-psma-617-shows-potential-in-mhspc-urology-times 2024-09-17T23:47:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/upfrontpsma-177lu-psma-617-shows-potential-in-mhspc-urology-times 2024-09-17T23:47:15+00:00 weekly 0.7 https://trial.medpath.com/news/ai-driven-saliva-test-revolutionizes-epilepsy-home-care-mirage-news 2024-09-17T23:24:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-driven-saliva-test-revolutionizes-epilepsy-home-care-mirage-news 2024-09-17T23:24:43+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-pembrolizumab-chemo-in-unresectable-pleural-mesothelioma 2024-09-17T23:22:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-pembrolizumab-chemo-in-unresectable-pleural-mesothelioma 2024-09-17T23:22:28+00:00 weekly 0.7 https://trial.medpath.com/news/cdmo-kincell-secures-partnership-to-manufacture-cell-therapy-for-clinical-trials 2024-09-17T23:22:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cdmo-kincell-secures-partnership-to-manufacture-cell-therapy-for-clinical-trials 2024-09-17T23:22:16+00:00 weekly 0.7 https://trial.medpath.com/news/trishula-therapeutics-reports-results-from-phase-i-trial-of-pancreatic-cancer-drug 2024-09-17T22:55:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/trishula-therapeutics-reports-results-from-phase-i-trial-of-pancreatic-cancer-drug 2024-09-17T22:55:08+00:00 weekly 0.7 https://trial.medpath.com/news/microbot-medical-announces-the-successful-enrollment-of-50-of-the-patients-in-its-pivotal 2024-09-17T22:36:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/microbot-medical-announces-the-successful-enrollment-of-50-of-the-patients-in-its-pivotal 2024-09-17T22:36:55+00:00 weekly 0.7 https://trial.medpath.com/news/biogen-s-new-drug-submission-for-omaveloxolone-accepted-for-priority-review-by-health 2024-09-17T22:36:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biogen-s-new-drug-submission-for-omaveloxolone-accepted-for-priority-review-by-health 2024-09-17T22:36:54+00:00 weekly 0.7 https://trial.medpath.com/news/sysmex-inostics-ras-raf-seq-assay-receives-new-york-state-department-of-health 2024-09-17T22:36:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sysmex-inostics-ras-raf-seq-assay-receives-new-york-state-department-of-health 2024-09-17T22:36:53+00:00 weekly 0.7 https://trial.medpath.com/news/lisata-therapeutics-announces-first-patient-treated-in-the-second-line-biospace 2024-09-17T22:36:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lisata-therapeutics-announces-first-patient-treated-in-the-second-line-biospace 2024-09-17T22:36:52+00:00 weekly 0.7 https://trial.medpath.com/news/q-a-ethical-decision-making-around-neurotechnology-treatments-penn-state-university 2024-09-17T22:18:44+00:00 weekly 0.7 https://trial.medpath.com/zh/news/q-a-ethical-decision-making-around-neurotechnology-treatments-penn-state-university 2024-09-17T22:18:44+00:00 weekly 0.7 https://trial.medpath.com/news/cms-new-breakthrough-device-policy-shows-little-promise-law360 2024-09-17T21:23:35+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cms-new-breakthrough-device-policy-shows-little-promise-law360 2024-09-17T21:23:35+00:00 weekly 0.7 https://trial.medpath.com/news/dr-mehta-on-fda-approved-treatment-options-in-later-line-hematologic-malignancies 2024-09-17T21:21:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-mehta-on-fda-approved-treatment-options-in-later-line-hematologic-malignancies 2024-09-17T21:21:05+00:00 weekly 0.7 https://trial.medpath.com/news/patients-at-last-begin-receiving-vertex-crispr-and-bluebird-sickle-cell-gene-therapies 2024-09-17T21:10:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/patients-at-last-begin-receiving-vertex-crispr-and-bluebird-sickle-cell-gene-therapies 2024-09-17T21:10:13+00:00 weekly 0.7 https://trial.medpath.com/news/fda-s-final-guidance-on-dcts-adds-clarity-on-hcp-task-log-inspection-requirements-data-variability 2024-09-17T21:09:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-s-final-guidance-on-dcts-adds-clarity-on-hcp-task-log-inspection-requirements-data-variability 2024-09-17T21:09:18+00:00 weekly 0.7 https://trial.medpath.com/news/should-young-kids-take-the-new-anti-obesity-drugs-what-the-research-says-nature 2024-09-17T21:05:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/should-young-kids-take-the-new-anti-obesity-drugs-what-the-research-says-nature 2024-09-17T21:05:31+00:00 weekly 0.7 https://trial.medpath.com/news/keytruda-keys-in-on-survival-promising-results-in-high-risk-early-stage-tnbc-from-keynote-522 2024-09-17T20:41:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/keytruda-keys-in-on-survival-promising-results-in-high-risk-early-stage-tnbc-from-keynote-522 2024-09-17T20:41:25+00:00 weekly 0.7 https://trial.medpath.com/news/an-oral-benzothiophene-bdk-inhibitor-disclosed-by-pfizer 2024-09-17T20:36:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/an-oral-benzothiophene-bdk-inhibitor-disclosed-by-pfizer 2024-09-17T20:36:22+00:00 weekly 0.7 https://trial.medpath.com/news/study-oncology-accelerated-approvals-are-often-based-on-non-comparative-trials-raps 2024-09-17T20:34:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/study-oncology-accelerated-approvals-are-often-based-on-non-comparative-trials-raps 2024-09-17T20:34:13+00:00 weekly 0.7 https://trial.medpath.com/news/elon-musk-s-neuralink-secures-fda-breakthrough-status-for-vision-implant 2024-09-17T20:26:41+00:00 weekly 0.7 https://trial.medpath.com/zh/news/elon-musk-s-neuralink-secures-fda-breakthrough-status-for-vision-implant 2024-09-17T20:26:41+00:00 weekly 0.7 https://trial.medpath.com/news/bubs-australia-asx-bub-one-of-the-few-infant-formula-stocks-building-a-post-china-future 2024-09-17T20:08:28+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bubs-australia-asx-bub-one-of-the-few-infant-formula-stocks-building-a-post-china-future 2024-09-17T20:08:28+00:00 weekly 0.7 https://trial.medpath.com/news/senseonics-receives-fda-clearance-for-one-year-cgm-medtech-dive 2024-09-17T19:57:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/senseonics-receives-fda-clearance-for-one-year-cgm-medtech-dive 2024-09-17T19:57:38+00:00 weekly 0.7 https://trial.medpath.com/news/metabolic-dysfunction-associated-steatohepatitis-mash-clinical-program-design 2024-09-17T19:45:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/metabolic-dysfunction-associated-steatohepatitis-mash-clinical-program-design 2024-09-17T19:45:59+00:00 weekly 0.7 https://trial.medpath.com/news/asv-is-not-a-generic-device-sleep-review 2024-09-17T19:45:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/asv-is-not-a-generic-device-sleep-review 2024-09-17T19:45:46+00:00 weekly 0.7 https://trial.medpath.com/news/musk-s-neuralink-gets-fda-s-breakthrough-device-tag-for-blindsight-implant-cna 2024-09-17T19:41:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/musk-s-neuralink-gets-fda-s-breakthrough-device-tag-for-blindsight-implant-cna 2024-09-17T19:41:18+00:00 weekly 0.7 https://trial.medpath.com/news/i-choose-to-climb-instead-of-fall-nih-medlineplus-magazine 2024-09-17T19:35:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/i-choose-to-climb-instead-of-fall-nih-medlineplus-magazine 2024-09-17T19:35:57+00:00 weekly 0.7 https://trial.medpath.com/news/quidelortho-receives-fda-approval-for-std-assay-san-diego-business-journal 2024-09-17T19:08:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/quidelortho-receives-fda-approval-for-std-assay-san-diego-business-journal 2024-09-17T19:08:10+00:00 weekly 0.7 https://trial.medpath.com/news/enhanced-cytosine-base-editing-for-duchenne-muscular-dystrophy-crispr-medicine 2024-09-17T18:55:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/enhanced-cytosine-base-editing-for-duchenne-muscular-dystrophy-crispr-medicine 2024-09-17T18:55:34+00:00 weekly 0.7 https://trial.medpath.com/news/sparta-biomedical-reports-treatment-of-first-patients-with-breakthrough-device-ormi 2024-09-17T18:54:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sparta-biomedical-reports-treatment-of-first-patients-with-breakthrough-device-ormi 2024-09-17T18:54:18+00:00 weekly 0.7 https://trial.medpath.com/news/allclinicaltrials-com-empowering-patients-with-easy-access-to-clinical-trials-the-globe-and-mail 2024-09-17T18:28:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/allclinicaltrials-com-empowering-patients-with-easy-access-to-clinical-trials-the-globe-and-mail 2024-09-17T18:28:21+00:00 weekly 0.7 https://trial.medpath.com/news/data-roundup-august-2024-features-updates-in-car-t-mrna-therapy-and-gamma 2024-09-17T18:14:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/data-roundup-august-2024-features-updates-in-car-t-mrna-therapy-and-gamma 2024-09-17T18:14:49+00:00 weekly 0.7 https://trial.medpath.com/news/fred-saad-md-on-implications-of-phase-3-aranote-data-in-mhspc-urology-times 2024-09-17T18:08:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fred-saad-md-on-implications-of-phase-3-aranote-data-in-mhspc-urology-times 2024-09-17T18:08:43+00:00 weekly 0.7 https://trial.medpath.com/news/cms-finalizes-new-transitional-coverage-for-emerging-technologies-tcet-pathway-to 2024-09-17T18:07:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cms-finalizes-new-transitional-coverage-for-emerging-technologies-tcet-pathway-to 2024-09-17T18:07:09+00:00 weekly 0.7 https://trial.medpath.com/news/benmelstobart-plus-anlotinib-demonstrates-efficacy-in-frontline-advanced-rcc-onclive 2024-09-17T18:06:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/benmelstobart-plus-anlotinib-demonstrates-efficacy-in-frontline-advanced-rcc-onclive 2024-09-17T18:06:12+00:00 weekly 0.7 https://trial.medpath.com/news/iview-therapeutics-inc-completes-patient-recruitment-for-phase-1-2-trial-of-ivw-1001 2024-09-17T17:08:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/iview-therapeutics-inc-completes-patient-recruitment-for-phase-1-2-trial-of-ivw-1001 2024-09-17T17:08:39+00:00 weekly 0.7 https://trial.medpath.com/news/damaged-small-intestine-repaired-with-hpsc-derived-organoids-drug-target-review 2024-09-17T17:03:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/damaged-small-intestine-repaired-with-hpsc-derived-organoids-drug-target-review 2024-09-17T17:03:47+00:00 weekly 0.7 https://trial.medpath.com/news/patritumab-deruxtecan-demonstrated-statistically-significant-improvement-in-progression 2024-09-17T16:50:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/patritumab-deruxtecan-demonstrated-statistically-significant-improvement-in-progression 2024-09-17T16:50:26+00:00 weekly 0.7 https://trial.medpath.com/news/leigh-s-lost-and-found-digital-extra-area-dogs-participate-in-study-to-extend-lives-ky3 2024-09-17T16:48:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/leigh-s-lost-and-found-digital-extra-area-dogs-participate-in-study-to-extend-lives-ky3 2024-09-17T16:48:46+00:00 weekly 0.7 https://trial.medpath.com/news/canaccord-highlights-arcturus-stock-potential-amid-regulatory-wins-investing-com 2024-09-17T16:45:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/canaccord-highlights-arcturus-stock-potential-amid-regulatory-wins-investing-com 2024-09-17T16:45:02+00:00 weekly 0.7 https://trial.medpath.com/news/medical-marijuana-users-see-short-term-gains-in-health-related-quality-of-life-study-finds 2024-09-17T16:44:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medical-marijuana-users-see-short-term-gains-in-health-related-quality-of-life-study-finds 2024-09-17T16:44:06+00:00 weekly 0.7 https://trial.medpath.com/news/desai-sethi-research-team-identifies-how-to-reverse-the-genetics-of-poor-prostate-cancer 2024-09-17T16:17:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/desai-sethi-research-team-identifies-how-to-reverse-the-genetics-of-poor-prostate-cancer 2024-09-17T16:17:58+00:00 weekly 0.7 https://trial.medpath.com/news/use-of-metformin-in-adults-with-diabetes-linked-to-lower-risk-of-long-covid 2024-09-17T16:16:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/use-of-metformin-in-adults-with-diabetes-linked-to-lower-risk-of-long-covid 2024-09-17T16:16:18+00:00 weekly 0.7 https://trial.medpath.com/news/ev-pembrolizumab-yields-pfs-os-orr-benefits-regardless-of-nectin-4-level 2024-09-17T16:03:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ev-pembrolizumab-yields-pfs-os-orr-benefits-regardless-of-nectin-4-level 2024-09-17T16:03:22+00:00 weekly 0.7 https://trial.medpath.com/news/new-drug-target-discovered-for-aggressive-prostate-cancer 2024-09-17T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-drug-target-discovered-for-aggressive-prostate-cancer 2024-09-17T16:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-2024-eli-lilly-brings-the-competition-to-novartis-with-new-results-in-mcrpc 2024-09-17T15:59:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/esmo-2024-eli-lilly-brings-the-competition-to-novartis-with-new-results-in-mcrpc 2024-09-17T15:59:36+00:00 weekly 0.7 https://trial.medpath.com/news/tislelizumab-receives-israeli-approval-in-unresectable-or-metastatic-escc-onclive 2024-09-17T15:43:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tislelizumab-receives-israeli-approval-in-unresectable-or-metastatic-escc-onclive 2024-09-17T15:43:37+00:00 weekly 0.7 https://trial.medpath.com/news/boehringer-gets-the-first-phase-iii-hit-in-ipf-for-a-decade-scrip-citeline 2024-09-17T15:37:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/boehringer-gets-the-first-phase-iii-hit-in-ipf-for-a-decade-scrip-citeline 2024-09-17T15:37:17+00:00 weekly 0.7 https://trial.medpath.com/news/obesity-pill-races-heats-up-as-novo-roche-and-terns-share-data-biospace 2024-09-17T15:23:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/obesity-pill-races-heats-up-as-novo-roche-and-terns-share-data-biospace 2024-09-17T15:23:11+00:00 weekly 0.7 https://trial.medpath.com/news/tomosynthesis-more-effective-than-mammography-for-breast-cancer-screening 2024-09-17T14:08:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tomosynthesis-more-effective-than-mammography-for-breast-cancer-screening 2024-09-17T14:08:07+00:00 weekly 0.7 https://trial.medpath.com/news/survival-improves-with-atezolizumab-switch-therapy-in-braf-melanoma 2024-09-17T14:03:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/survival-improves-with-atezolizumab-switch-therapy-in-braf-melanoma 2024-09-17T14:03:39+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-24-pfizer-to-take-cancer-weight-gain-drug-into-phase-iii-scrip-citeline 2024-09-17T14:03:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/esmo-24-pfizer-to-take-cancer-weight-gain-drug-into-phase-iii-scrip-citeline 2024-09-17T14:03:06+00:00 weekly 0.7 https://trial.medpath.com/news/cps-technologies-corporation-announces-phase-ii-award-from-the-department-of-energy 2024-09-17T13:43:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cps-technologies-corporation-announces-phase-ii-award-from-the-department-of-energy 2024-09-17T13:43:46+00:00 weekly 0.7 https://trial.medpath.com/news/inmune-bio-announces-results-of-additional-blinded-interim-analysis-of-phase-2-morningstar 2024-09-17T13:33:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inmune-bio-announces-results-of-additional-blinded-interim-analysis-of-phase-2-morningstar 2024-09-17T13:33:33+00:00 weekly 0.7 https://trial.medpath.com/news/immunos-therapeutics-ag-raises-us-11m-in-series-c-financing-european-biotechnology 2024-09-17T13:20:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immunos-therapeutics-ag-raises-us-11m-in-series-c-financing-european-biotechnology 2024-09-17T13:20:13+00:00 weekly 0.7 https://trial.medpath.com/news/us-fda-approval-total-knee-study-company-announcement-investegate 2024-09-17T13:04:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/us-fda-approval-total-knee-study-company-announcement-investegate 2024-09-17T13:04:20+00:00 weekly 0.7 https://trial.medpath.com/news/ritedose-is-proud-to-partner-with-verona-pharma-to-deliver-first-in-class-copd-drug 2024-09-17T12:30:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ritedose-is-proud-to-partner-with-verona-pharma-to-deliver-first-in-class-copd-drug 2024-09-17T12:30:21+00:00 weekly 0.7 https://trial.medpath.com/news/ohio-state-s-novel-dhodh-inhibitor-enters-first-human-trials-news-medical 2024-09-17T12:27:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ohio-state-s-novel-dhodh-inhibitor-enters-first-human-trials-news-medical 2024-09-17T12:27:37+00:00 weekly 0.7 https://trial.medpath.com/news/glp-1s-can-potentially-cut-cirrhosis-related-complications-in-masld-study-biospace 2024-09-17T12:26:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/glp-1s-can-potentially-cut-cirrhosis-related-complications-in-masld-study-biospace 2024-09-17T12:26:00+00:00 weekly 0.7 https://trial.medpath.com/news/leukemia-survivor-breast-cancer-caregiver-why-i-joined-md-anderson-s-boot-walk-to-end 2024-09-17T12:16:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/leukemia-survivor-breast-cancer-caregiver-why-i-joined-md-anderson-s-boot-walk-to-end 2024-09-17T12:16:01+00:00 weekly 0.7 https://trial.medpath.com/news/endomimeticstm-awarded-2-8-million-phase-ii-sbir-grant-to-globenewswire 2024-09-17T12:07:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/endomimeticstm-awarded-2-8-million-phase-ii-sbir-grant-to-globenewswire 2024-09-17T12:07:33+00:00 weekly 0.7 https://trial.medpath.com/news/rosacea-in-patients-of-color-experts-call-for-better-recognition-and-diagnosis 2024-09-17T12:00:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rosacea-in-patients-of-color-experts-call-for-better-recognition-and-diagnosis 2024-09-17T12:00:57+00:00 weekly 0.7 https://trial.medpath.com/news/bridgebio-announces-infigratinib-is-the-first-ever-investigational-therapeutic-option-stock-titan 2024-09-17T11:47:12+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bridgebio-announces-infigratinib-is-the-first-ever-investigational-therapeutic-option-stock-titan 2024-09-17T11:47:12+00:00 weekly 0.7 https://trial.medpath.com/news/innovation-driving-cancer-s-solid-tumors-market-aemd-stock-news 2024-09-17T11:45:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/innovation-driving-cancer-s-solid-tumors-market-aemd-stock-news 2024-09-17T11:45:59+00:00 weekly 0.7 https://trial.medpath.com/news/rocket-pharmaceuticals-announces-completion-of-enrollment-in-phase-2-pivotal-trial-of-rp 2024-09-17T11:45:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rocket-pharmaceuticals-announces-completion-of-enrollment-in-phase-2-pivotal-trial-of-rp 2024-09-17T11:45:08+00:00 weekly 0.7 https://trial.medpath.com/news/transcode-therapeutics-announces-first-patients-treated-in-phase-1-clinical-trial-with 2024-09-17T11:44:29+00:00 weekly 0.7 https://trial.medpath.com/zh/news/transcode-therapeutics-announces-first-patients-treated-in-phase-1-clinical-trial-with 2024-09-17T11:44:29+00:00 weekly 0.7 https://trial.medpath.com/news/guard-therapeutics-phase-2-results-published-in-leading-scientific-journal-placera 2024-09-17T11:35:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/guard-therapeutics-phase-2-results-published-in-leading-scientific-journal-placera 2024-09-17T11:35:26+00:00 weekly 0.7 https://trial.medpath.com/news/poseida-therapeutics-p-bcma-allo1-receives-us-fda-rmat-designation-to-treat 2024-09-17T11:30:18+00:00 weekly 0.7 https://trial.medpath.com/zh/news/poseida-therapeutics-p-bcma-allo1-receives-us-fda-rmat-designation-to-treat 2024-09-17T11:30:18+00:00 weekly 0.7 https://trial.medpath.com/news/beigene-receives-israeli-ministry-of-health-approval-for-tevimbra-r-for-the-treatment-of 2024-09-17T11:12:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/beigene-receives-israeli-ministry-of-health-approval-for-tevimbra-r-for-the-treatment-of 2024-09-17T11:12:10+00:00 weekly 0.7 https://trial.medpath.com/news/cullinan-therapeutics-receives-approval-to-initiate-its-global-phase-1-clinical-trial-of-cln 2024-09-17T11:04:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cullinan-therapeutics-receives-approval-to-initiate-its-global-phase-1-clinical-trial-of-cln 2024-09-17T11:04:33+00:00 weekly 0.7 https://trial.medpath.com/news/boston-scientific-receives-fda-approval-for-expanded-indication-of-ingevitytm-pacing 2024-09-17T11:01:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/boston-scientific-receives-fda-approval-for-expanded-indication-of-ingevitytm-pacing 2024-09-17T11:01:01+00:00 weekly 0.7 https://trial.medpath.com/news/synbiotics-in-patients-at-risk-for-spontaneous-preterm-birth-protocol-for-a-multi-centre 2024-09-17T10:33:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/synbiotics-in-patients-at-risk-for-spontaneous-preterm-birth-protocol-for-a-multi-centre 2024-09-17T10:33:23+00:00 weekly 0.7 https://trial.medpath.com/news/ascletis-enters-the-obesity-drug-space-with-announcement-of-two-ongoing-u-s-phase-i 2024-09-17T10:26:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ascletis-enters-the-obesity-drug-space-with-announcement-of-two-ongoing-u-s-phase-i 2024-09-17T10:26:17+00:00 weekly 0.7 https://trial.medpath.com/news/ferrer-advances-research-into-progressive-supranuclear-palsy-psp-with-the-inclusion-of 2024-09-17T09:57:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ferrer-advances-research-into-progressive-supranuclear-palsy-psp-with-the-inclusion-of 2024-09-17T09:57:08+00:00 weekly 0.7 https://trial.medpath.com/news/little-pre-and-postmarket-testing-for-most-recalled-cv-devices-tctmd-com 2024-09-17T09:35:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/little-pre-and-postmarket-testing-for-most-recalled-cv-devices-tctmd-com 2024-09-17T09:35:05+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-phase-iii-natalee-trial-of-kisqali-shows-deepening-benefit-in-new-analysis 2024-09-17T09:29:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-phase-iii-natalee-trial-of-kisqali-shows-deepening-benefit-in-new-analysis 2024-09-17T09:29:25+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-s-imfinzi-and-imjudo-found-to-extend-survival-in-liver-cancer-trial 2024-09-17T09:17:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-s-imfinzi-and-imjudo-found-to-extend-survival-in-liver-cancer-trial 2024-09-17T09:17:43+00:00 weekly 0.7 https://trial.medpath.com/news/combo-treatment-doubles-survival-for-patients-with-advanced-kidney-cancer 2024-09-17T09:09:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/combo-treatment-doubles-survival-for-patients-with-advanced-kidney-cancer 2024-09-17T09:09:40+00:00 weekly 0.7 https://trial.medpath.com/news/pipeline-watch-four-approvals-and-32-phase-iii-readouts-scrip-citeline 2024-09-17T08:38:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pipeline-watch-four-approvals-and-32-phase-iii-readouts-scrip-citeline 2024-09-17T08:38:45+00:00 weekly 0.7 https://trial.medpath.com/news/minervax-and-wacker-biotech-announce-manufacturing-collaboration-for-prophylactic 2024-09-17T07:31:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/minervax-and-wacker-biotech-announce-manufacturing-collaboration-for-prophylactic 2024-09-17T07:31:49+00:00 weekly 0.7 https://trial.medpath.com/news/expert-highlights-critical-role-of-early-diagnosis-and-targeted-therapy-in-bpdcn-management 2024-09-17T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/expert-highlights-critical-role-of-early-diagnosis-and-targeted-therapy-in-bpdcn-management 2024-09-17T07:00:00+00:00 weekly 0.7 https://trial.medpath.com/news/karolinska-development-s-portfolio-company-anacardio-reports-progress-in-two-clinical 2024-09-17T06:39:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/karolinska-development-s-portfolio-company-anacardio-reports-progress-in-two-clinical 2024-09-17T06:39:33+00:00 weekly 0.7 https://trial.medpath.com/news/studies-show-immunotherapy-improves-long-term-survival-in-growing-number-of-cancers 2024-09-17T05:42:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/studies-show-immunotherapy-improves-long-term-survival-in-growing-number-of-cancers 2024-09-17T05:42:49+00:00 weekly 0.7 https://trial.medpath.com/news/mortality-and-functional-outcomes-18-months-after-hospitalization-for-covid-19-in-geriatric-patients 2024-09-17T05:36:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/mortality-and-functional-outcomes-18-months-after-hospitalization-for-covid-19-in-geriatric-patients 2024-09-17T05:36:39+00:00 weekly 0.7 https://trial.medpath.com/news/ai-powered-data-integration-revolutionizes-drug-diversion-detection-in-healthcare-systems 2024-09-17T05:14:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ai-powered-data-integration-revolutionizes-drug-diversion-detection-in-healthcare-systems 2024-09-17T05:14:20+00:00 weekly 0.7 https://trial.medpath.com/news/gene-therapy-clinical-trials-2024-ema-pdma-fda-approvals-openpr-com 2024-09-17T04:51:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gene-therapy-clinical-trials-2024-ema-pdma-fda-approvals-openpr-com 2024-09-17T04:51:08+00:00 weekly 0.7 https://trial.medpath.com/news/spinal-muscular-atrophy-clinical-trials-2024-updated-ema-openpr-com 2024-09-17T04:33:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/spinal-muscular-atrophy-clinical-trials-2024-updated-ema-openpr-com 2024-09-17T04:33:55+00:00 weekly 0.7 https://trial.medpath.com/news/lykos-could-see-five-year-delay-in-possible-fda-approval-of-mdma-inside-health-policy 2024-09-17T02:17:20+00:00 weekly 0.7 https://trial.medpath.com/zh/news/lykos-could-see-five-year-delay-in-possible-fda-approval-of-mdma-inside-health-policy 2024-09-17T02:17:20+00:00 weekly 0.7 https://trial.medpath.com/news/fda-issues-draft-guidance-on-conducting-multiregional-clinical-trials-in-oncology 2024-09-17T02:07:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-issues-draft-guidance-on-conducting-multiregional-clinical-trials-in-oncology 2024-09-17T02:07:22+00:00 weekly 0.7 https://trial.medpath.com/news/pds-biotech-announces-updated-results-from-versatile-002-phase-2-clinical-trial 2024-09-17T02:07:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pds-biotech-announces-updated-results-from-versatile-002-phase-2-clinical-trial 2024-09-17T02:07:19+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-2024-fecal-microbiota-transplantation-vs-placebo-in-patients-receiving-urotoday 2024-09-17T01:35:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/esmo-2024-fecal-microbiota-transplantation-vs-placebo-in-patients-receiving-urotoday 2024-09-17T01:35:45+00:00 weekly 0.7 https://trial.medpath.com/news/astrazeneca-s-perioperative-imfinzi-significantly-extends-survival-in-type-of-bladder-cancer 2024-09-17T01:10:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/astrazeneca-s-perioperative-imfinzi-significantly-extends-survival-in-type-of-bladder-cancer 2024-09-17T01:10:11+00:00 weekly 0.7 https://trial.medpath.com/news/pharmaust-seeks-european-orphan-drug-designation-for-mnd-als-drug-monepantel 2024-09-17T00:43:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pharmaust-seeks-european-orphan-drug-designation-for-mnd-als-drug-monepantel 2024-09-17T00:43:13+00:00 weekly 0.7 https://trial.medpath.com/news/drug-safety-experts-call-for-enhanced-diagnostic-accuracy-in-clinical-trials-to-protect-patient-safety 2024-09-17T00:30:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/drug-safety-experts-call-for-enhanced-diagnostic-accuracy-in-clinical-trials-to-protect-patient-safety 2024-09-17T00:30:00+00:00 weekly 0.7 https://trial.medpath.com/news/ipf-drug-meets-primary-end-point-managed-healthcare-executive 2024-09-17T00:24:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ipf-drug-meets-primary-end-point-managed-healthcare-executive 2024-09-17T00:24:40+00:00 weekly 0.7 https://trial.medpath.com/news/launch-of-yselty-r-generic-name-linzagolix-for-uterine-fibroid-treatment-in-europe 2024-09-17T00:21:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/launch-of-yselty-r-generic-name-linzagolix-for-uterine-fibroid-treatment-in-europe 2024-09-17T00:21:55+00:00 weekly 0.7 https://trial.medpath.com/news/5-year-analysis-of-phase-iii-himalaya-confirms-survival-benefit-of-stride-in 2024-09-16T22:22:58+00:00 weekly 0.7 https://trial.medpath.com/zh/news/5-year-analysis-of-phase-iii-himalaya-confirms-survival-benefit-of-stride-in 2024-09-16T22:22:58+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-manufacturing-line-for-rsv-therapy-becker-s-hospital-review 2024-09-16T21:58:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-manufacturing-line-for-rsv-therapy-becker-s-hospital-review 2024-09-16T21:58:48+00:00 weekly 0.7 https://trial.medpath.com/news/elderly-monkeys-aged-more-slowly-when-given-a-cheap-diabetes-drug-used-by-millions 2024-09-16T21:42:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/elderly-monkeys-aged-more-slowly-when-given-a-cheap-diabetes-drug-used-by-millions 2024-09-16T21:42:16+00:00 weekly 0.7 https://trial.medpath.com/news/darolutamide-in-combination-with-androgen-deprivation-therapy-in-patients-with-urotoday 2024-09-16T21:25:51+00:00 weekly 0.7 https://trial.medpath.com/zh/news/darolutamide-in-combination-with-androgen-deprivation-therapy-in-patients-with-urotoday 2024-09-16T21:25:51+00:00 weekly 0.7 https://trial.medpath.com/news/qu-scientists-in-precision-medicine-breakthrough-gulf-times 2024-09-16T21:08:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/qu-scientists-in-precision-medicine-breakthrough-gulf-times 2024-09-16T21:08:54+00:00 weekly 0.7 https://trial.medpath.com/news/pei-yu-chen-phd-aims-to-create-a-safer-and-more-effective-way-to-deliver-drugs 2024-09-16T21:07:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pei-yu-chen-phd-aims-to-create-a-safer-and-more-effective-way-to-deliver-drugs 2024-09-16T21:07:48+00:00 weekly 0.7 https://trial.medpath.com/news/phase-2-trial-highlights-potential-of-inavolisib-for-pik3ca-mutated-cancers 2024-09-16T21:03:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/phase-2-trial-highlights-potential-of-inavolisib-for-pik3ca-mutated-cancers 2024-09-16T21:03:01+00:00 weekly 0.7 https://trial.medpath.com/news/poor-outcomes-after-tpoxx-mpox-treatment-mainly-seen-in-those-with-weak-immunity 2024-09-16T20:47:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/poor-outcomes-after-tpoxx-mpox-treatment-mainly-seen-in-those-with-weak-immunity 2024-09-16T20:47:54+00:00 weekly 0.7 https://trial.medpath.com/news/biotronik-catheter-gets-fda-approval-daic 2024-09-16T20:44:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biotronik-catheter-gets-fda-approval-daic 2024-09-16T20:44:43+00:00 weekly 0.7 https://trial.medpath.com/news/duke-physician-highlights-positive-ovarian-cancer-clinical-trial-results 2024-09-16T20:44:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/duke-physician-highlights-positive-ovarian-cancer-clinical-trial-results 2024-09-16T20:44:37+00:00 weekly 0.7 https://trial.medpath.com/news/amg-193-shows-preliminary-clinical-activity-in-mtap-deleted-solid-tumors-onclive 2024-09-16T20:28:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/amg-193-shows-preliminary-clinical-activity-in-mtap-deleted-solid-tumors-onclive 2024-09-16T20:28:10+00:00 weekly 0.7 https://trial.medpath.com/news/brain-metastases-of-her2-positive-breast-cancer-patients-effectively-treated-with-antibody 2024-09-16T20:23:13+00:00 weekly 0.7 https://trial.medpath.com/zh/news/brain-metastases-of-her2-positive-breast-cancer-patients-effectively-treated-with-antibody 2024-09-16T20:23:13+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-apple-watch-sleep-apnea-detection-notification-appleinsider 2024-09-16T20:14:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-apple-watch-sleep-apnea-detection-notification-appleinsider 2024-09-16T20:14:00+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-mm-ii-fast-track-designation-for-treatment-of-osteoarthritis-knee-pain 2024-09-16T20:09:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-mm-ii-fast-track-designation-for-treatment-of-osteoarthritis-knee-pain 2024-09-16T20:09:56+00:00 weekly 0.7 https://trial.medpath.com/news/fda-drafts-guidance-on-multiregional-clinical-trials-in-oncology-raps 2024-09-16T19:49:38+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-drafts-guidance-on-multiregional-clinical-trials-in-oncology-raps 2024-09-16T19:49:38+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-lebrikizumab-for-treatment-of-atopic-dermatitis-pharmacy-times 2024-09-16T19:48:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-lebrikizumab-for-treatment-of-atopic-dermatitis-pharmacy-times 2024-09-16T19:48:49+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approval-insights-epcoritamab-in-relapsed-refractory-follicular-lymphoma-onclive 2024-09-16T19:44:49+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approval-insights-epcoritamab-in-relapsed-refractory-follicular-lymphoma-onclive 2024-09-16T19:44:49+00:00 weekly 0.7 https://trial.medpath.com/news/researchers-announce-clinical-trial-results-for-hard-to-treat-breast-and-bladder-cancers 2024-09-16T19:39:53+00:00 weekly 0.7 https://trial.medpath.com/zh/news/researchers-announce-clinical-trial-results-for-hard-to-treat-breast-and-bladder-cancers 2024-09-16T19:39:53+00:00 weekly 0.7 https://trial.medpath.com/news/regeneron-sny-win-fda-approval-for-a-broader-dupixent-label-yahoo-finance 2024-09-16T19:08:43+00:00 weekly 0.7 https://trial.medpath.com/zh/news/regeneron-sny-win-fda-approval-for-a-broader-dupixent-label-yahoo-finance 2024-09-16T19:08:43+00:00 weekly 0.7 https://trial.medpath.com/news/newly-initiated-phase-2-breakthrough-trial-to-test-5-ht2c-receptor-agonist-bmb-101 2024-09-16T19:08:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/newly-initiated-phase-2-breakthrough-trial-to-test-5-ht2c-receptor-agonist-bmb-101 2024-09-16T19:08:27+00:00 weekly 0.7 https://trial.medpath.com/news/keynote-522-findings-continue-to-shape-the-future-of-tnbc-care-targeted-oncology 2024-09-16T19:05:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/keynote-522-findings-continue-to-shape-the-future-of-tnbc-care-targeted-oncology 2024-09-16T19:05:19+00:00 weekly 0.7 https://trial.medpath.com/news/pembrolizumab-improves-outcomes-in-high-risk-bladder-cancer-nci 2024-09-16T18:44:32+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pembrolizumab-improves-outcomes-in-high-risk-bladder-cancer-nci 2024-09-16T18:44:32+00:00 weekly 0.7 https://trial.medpath.com/news/techcrunch-minute-fda-approval-sets-the-stage-for-apple-s-airpod-hearing-aids 2024-09-16T18:38:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/techcrunch-minute-fda-approval-sets-the-stage-for-apple-s-airpod-hearing-aids 2024-09-16T18:38:27+00:00 weekly 0.7 https://trial.medpath.com/news/apple-gets-fda-approval-for-smartwatch-sleep-apnea-detection-feature-investopedia 2024-09-16T18:29:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/apple-gets-fda-approval-for-smartwatch-sleep-apnea-detection-feature-investopedia 2024-09-16T18:29:11+00:00 weekly 0.7 https://trial.medpath.com/news/tremelimumab-plus-durvalumab-turns-heads-with-updated-five-year-data-in-uhcc 2024-09-16T18:27:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/tremelimumab-plus-durvalumab-turns-heads-with-updated-five-year-data-in-uhcc 2024-09-16T18:27:31+00:00 weekly 0.7 https://trial.medpath.com/news/immunotherapy-and-novel-targeted-drug-appear-beneficial-in-women-with-early-stage 2024-09-16T18:27:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immunotherapy-and-novel-targeted-drug-appear-beneficial-in-women-with-early-stage 2024-09-16T18:27:09+00:00 weekly 0.7 https://trial.medpath.com/news/fda-clears-apple-s-sleep-apnea-detection-feature-for-use-here-s-how-it-works-cnbc 2024-09-16T18:12:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-clears-apple-s-sleep-apnea-detection-feature-for-use-here-s-how-it-works-cnbc 2024-09-16T18:12:04+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-ebglyss-for-moderate-to-severe-atopic-dermatitis-pharmaceutical-executive 2024-09-16T18:09:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-ebglyss-for-moderate-to-severe-atopic-dermatitis-pharmaceutical-executive 2024-09-16T18:09:15+00:00 weekly 0.7 https://trial.medpath.com/news/new-eli-lilly-eczema-drug-brings-competition-and-dosing-edge-versus-sanofi-leo-pharma-meds 2024-09-16T17:56:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-eli-lilly-eczema-drug-brings-competition-and-dosing-edge-versus-sanofi-leo-pharma-meds 2024-09-16T17:56:47+00:00 weekly 0.7 https://trial.medpath.com/news/eli-lilly-scores-fda-approval-for-eczema-treatment-ebglyss-benzinga 2024-09-16T17:52:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/eli-lilly-scores-fda-approval-for-eczema-treatment-ebglyss-benzinga 2024-09-16T17:52:46+00:00 weekly 0.7 https://trial.medpath.com/news/recon-astrazeneca-releases-positive-results-on-imfinzi-for-bladder-cancer-raps 2024-09-16T17:26:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/recon-astrazeneca-releases-positive-results-on-imfinzi-for-bladder-cancer-raps 2024-09-16T17:26:56+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-biotronik-lead-catheter-for-left-bundle-branch-area-pacing 2024-09-16T17:20:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-biotronik-lead-catheter-for-left-bundle-branch-area-pacing 2024-09-16T17:20:09+00:00 weekly 0.7 https://trial.medpath.com/news/medical-marijuana-users-see-short-term-gains-in-he-newswise 2024-09-16T17:06:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/medical-marijuana-users-see-short-term-gains-in-he-newswise 2024-09-16T17:06:34+00:00 weekly 0.7 https://trial.medpath.com/news/evaxion-reports-convincing-one-year-data-from-phase-2-trial-on-ai-designed-personalized 2024-09-16T17:02:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/evaxion-reports-convincing-one-year-data-from-phase-2-trial-on-ai-designed-personalized 2024-09-16T17:02:55+00:00 weekly 0.7 https://trial.medpath.com/news/rewriting-the-health-care-script-in-africa-c-en-american-chemical-society 2024-09-16T16:48:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/rewriting-the-health-care-script-in-africa-c-en-american-chemical-society 2024-09-16T16:48:05+00:00 weekly 0.7 https://trial.medpath.com/news/dr-nicolas-girard-on-luminosity-teliso-v-improves-pros-in-nsclc 2024-09-16T16:47:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dr-nicolas-girard-on-luminosity-teliso-v-improves-pros-in-nsclc 2024-09-16T16:47:04+00:00 weekly 0.7 https://trial.medpath.com/news/dupixent-gains-fda-approval-for-expanded-use-in-adolescents-with-crswnp 2024-09-16T16:46:25+00:00 weekly 0.7 https://trial.medpath.com/zh/news/dupixent-gains-fda-approval-for-expanded-use-in-adolescents-with-crswnp 2024-09-16T16:46:25+00:00 weekly 0.7 https://trial.medpath.com/news/leigh-s-lost-and-found-local-vet-office-takes-part-in-clinical-trial-to-extend-dogs-lives-ky3 2024-09-16T16:42:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/leigh-s-lost-and-found-local-vet-office-takes-part-in-clinical-trial-to-extend-dogs-lives-ky3 2024-09-16T16:42:27+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-new-catheter-system-for-left-bundle-branch-area-pacing-healio 2024-09-16T16:35:11+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-new-catheter-system-for-left-bundle-branch-area-pacing-healio 2024-09-16T16:35:11+00:00 weekly 0.7 https://trial.medpath.com/news/icmr-signs-agreements-for-first-in-human-clinical-trials-of-four-new-molecules 2024-09-16T16:35:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/icmr-signs-agreements-for-first-in-human-clinical-trials-of-four-new-molecules 2024-09-16T16:35:08+00:00 weekly 0.7 https://trial.medpath.com/news/boehringer-s-nerandomilast-meets-primary-endpoint-in-pivotal-phase-iii-fibroneertm-ipf-study 2024-09-16T16:33:01+00:00 weekly 0.7 https://trial.medpath.com/zh/news/boehringer-s-nerandomilast-meets-primary-endpoint-in-pivotal-phase-iii-fibroneertm-ipf-study 2024-09-16T16:33:01+00:00 weekly 0.7 https://trial.medpath.com/news/inspiremd-submits-carotid-stent-for-fda-premarket-approval-massdevice 2024-09-16T16:28:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/inspiremd-submits-carotid-stent-for-fda-premarket-approval-massdevice 2024-09-16T16:28:03+00:00 weekly 0.7 https://trial.medpath.com/news/apple-watch-s-sleep-apnea-detection-feature-gets-fda-approval-here-s-how-it-will-work 2024-09-16T16:27:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/apple-watch-s-sleep-apnea-detection-feature-gets-fda-approval-here-s-how-it-will-work 2024-09-16T16:27:30+00:00 weekly 0.7 https://trial.medpath.com/news/pipeline-moves-novo-nordisk-s-liraglutide-scores-in-phase-iii-paediatric-trial 2024-09-16T16:24:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pipeline-moves-novo-nordisk-s-liraglutide-scores-in-phase-iii-paediatric-trial 2024-09-16T16:24:30+00:00 weekly 0.7 https://trial.medpath.com/news/apple-watch-sleep-apnea-detection-gets-fda-approval-healthleaders-media 2024-09-16T16:13:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/apple-watch-sleep-apnea-detection-gets-fda-approval-healthleaders-media 2024-09-16T16:13:15+00:00 weekly 0.7 https://trial.medpath.com/news/fda-lifts-hold-on-zentalis-cancer-drug-trials-investing-com 2024-09-16T16:09:40+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-lifts-hold-on-zentalis-cancer-drug-trials-investing-com 2024-09-16T16:09:40+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-ocrevus-zunovo-for-relapsing-primary-progressive-multiple-sclerosis 2024-09-16T16:08:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-ocrevus-zunovo-for-relapsing-primary-progressive-multiple-sclerosis 2024-09-16T16:08:55+00:00 weekly 0.7 https://trial.medpath.com/news/boehringer-seeks-approval-for-lung-fibrosis-drug-following-phase-iii-win-yahoo 2024-09-16T16:08:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/boehringer-seeks-approval-for-lung-fibrosis-drug-following-phase-iii-win-yahoo 2024-09-16T16:08:48+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-first-of-its-kind-cardiac-stent-for-babies-newswise 2024-09-16T16:08:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-first-of-its-kind-cardiac-stent-for-babies-newswise 2024-09-16T16:08:24+00:00 weekly 0.7 https://trial.medpath.com/news/50-years-of-the-cure-celebrating-pioneering-iu-research-and-the-cure-for-testicular-cancer 2024-09-16T16:07:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/50-years-of-the-cure-celebrating-pioneering-iu-research-and-the-cure-for-testicular-cancer 2024-09-16T16:07:02+00:00 weekly 0.7 https://trial.medpath.com/news/splash-177lu-pnt2002-achieves-phase-3-outcomes-for-mcrpc-urology-times 2024-09-16T16:04:04+00:00 weekly 0.7 https://trial.medpath.com/zh/news/splash-177lu-pnt2002-achieves-phase-3-outcomes-for-mcrpc-urology-times 2024-09-16T16:04:04+00:00 weekly 0.7 https://trial.medpath.com/news/immunotherapy-after-surgery-helps-people-with-high-risk-bladder-cancer-live-cancer-free-longer 2024-09-16T15:56:31+00:00 weekly 0.7 https://trial.medpath.com/zh/news/immunotherapy-after-surgery-helps-people-with-high-risk-bladder-cancer-live-cancer-free-longer 2024-09-16T15:56:31+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-nivolumab-or-nivolumab-plus-ipilimumab-in-early-stage-triple-negative-breast-cancer 2024-09-16T15:46:46+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neoadjuvant-nivolumab-or-nivolumab-plus-ipilimumab-in-early-stage-triple-negative-breast-cancer 2024-09-16T15:46:46+00:00 weekly 0.7 https://trial.medpath.com/news/ten-year-data-from-checkmate-067-trial-shows-long-term-survival-benefits-of-opdivo 2024-09-16T15:46:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ten-year-data-from-checkmate-067-trial-shows-long-term-survival-benefits-of-opdivo 2024-09-16T15:46:39+00:00 weekly 0.7 https://trial.medpath.com/news/imfinzi-plus-imjudo-shows-significant-five-year-survival-improvement-in-unresectable-liver-cancer 2024-09-16T15:46:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/imfinzi-plus-imjudo-shows-significant-five-year-survival-improvement-in-unresectable-liver-cancer 2024-09-16T15:46:39+00:00 weekly 0.7 https://trial.medpath.com/news/chemo-free-triplet-yields-68-response-rate-in-richter-transformation-medpage-today 2024-09-16T15:45:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/chemo-free-triplet-yields-68-response-rate-in-richter-transformation-medpage-today 2024-09-16T15:45:37+00:00 weekly 0.7 https://trial.medpath.com/news/new-eczema-drug-from-eli-lilly-receives-fda-approval-for-children-and-adults-usa-today 2024-09-16T15:42:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-eczema-drug-from-eli-lilly-receives-fda-approval-for-children-and-adults-usa-today 2024-09-16T15:42:45+00:00 weekly 0.7 https://trial.medpath.com/news/alliance-presents-final-results-from-phase-ii-eurekalert 2024-09-16T15:42:23+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alliance-presents-final-results-from-phase-ii-eurekalert 2024-09-16T15:42:23+00:00 weekly 0.7 https://trial.medpath.com/news/guru-sonpavde-md-on-phase-3-ambassador-trial-data-in-urothelial-carcinoma 2024-09-16T15:40:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/guru-sonpavde-md-on-phase-3-ambassador-trial-data-in-urothelial-carcinoma 2024-09-16T15:40:56+00:00 weekly 0.7 https://trial.medpath.com/news/pooled-trust-i-and-trust-ii-data-affirm-taletrectinib-benefits-for-advanced-ros1-nsclc 2024-09-16T15:40:17+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pooled-trust-i-and-trust-ii-data-affirm-taletrectinib-benefits-for-advanced-ros1-nsclc 2024-09-16T15:40:17+00:00 weekly 0.7 https://trial.medpath.com/news/fda-lifts-partial-clinical-hold-on-trials-evaluating-azenosertib-in-advanced-solid-tumors 2024-09-16T15:40:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-lifts-partial-clinical-hold-on-trials-evaluating-azenosertib-in-advanced-solid-tumors 2024-09-16T15:40:02+00:00 weekly 0.7 https://trial.medpath.com/news/fda-grants-p-bcma-allo1-rmat-designation-in-r-r-multiple-myeloma 2024-09-16T15:35:05+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-grants-p-bcma-allo1-rmat-designation-in-r-r-multiple-myeloma 2024-09-16T15:35:05+00:00 weekly 0.7 https://trial.medpath.com/news/epitomee-medical-announces-fda-clearance-of-its-capsule-weight-management-device 2024-09-16T15:21:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/epitomee-medical-announces-fda-clearance-of-its-capsule-weight-management-device 2024-09-16T15:21:37+00:00 weekly 0.7 https://trial.medpath.com/news/bayer-targets-expanded-use-approval-for-prostate-cancer-drug-reveals-encouraging 2024-09-16T15:21:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/bayer-targets-expanded-use-approval-for-prostate-cancer-drug-reveals-encouraging 2024-09-16T15:21:07+00:00 weekly 0.7 https://trial.medpath.com/news/biotronik-earns-expanded-fda-nod-for-pacing-lead-delivery-catheter-system-massdevice 2024-09-16T15:19:54+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biotronik-earns-expanded-fda-nod-for-pacing-lead-delivery-catheter-system-massdevice 2024-09-16T15:19:54+00:00 weekly 0.7 https://trial.medpath.com/news/addressing-disparities-in-food-allergen-immunotherapy-trials-jama-network 2024-09-16T15:18:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/addressing-disparities-in-food-allergen-immunotherapy-trials-jama-network 2024-09-16T15:18:16+00:00 weekly 0.7 https://trial.medpath.com/news/first-group-of-healthy-volunteers-dosed-in-qrl-101-mad-study-als-news-today 2024-09-16T15:14:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/first-group-of-healthy-volunteers-dosed-in-qrl-101-mad-study-als-news-today 2024-09-16T15:14:15+00:00 weekly 0.7 https://trial.medpath.com/news/epitomee-medical-announces-fda-clearance-of-its-capsule-weight-management-device 2024-09-16T15:13:03+00:00 weekly 0.7 https://trial.medpath.com/zh/news/epitomee-medical-announces-fda-clearance-of-its-capsule-weight-management-device 2024-09-16T15:13:03+00:00 weekly 0.7 https://trial.medpath.com/news/some-men-with-prostate-cancer-can-benefit-from-immunotherapy 2024-09-16T15:12:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/some-men-with-prostate-cancer-can-benefit-from-immunotherapy 2024-09-16T15:12:34+00:00 weekly 0.7 https://trial.medpath.com/news/apple-watch-sleep-apnea-detection-gets-fda-clearance-the-verge 2024-09-16T15:12:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/apple-watch-sleep-apnea-detection-gets-fda-clearance-the-verge 2024-09-16T15:12:30+00:00 weekly 0.7 https://trial.medpath.com/news/weekly-review-dupilumab-lebrikizumab-fda-approved-plus-much-more-contemporary-pediatrics 2024-09-16T15:11:59+00:00 weekly 0.7 https://trial.medpath.com/zh/news/weekly-review-dupilumab-lebrikizumab-fda-approved-plus-much-more-contemporary-pediatrics 2024-09-16T15:11:59+00:00 weekly 0.7 https://trial.medpath.com/news/ozempic-could-curb-progression-of-diabetes-linked-liver-disease 2024-09-16T15:09:52+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ozempic-could-curb-progression-of-diabetes-linked-liver-disease 2024-09-16T15:09:52+00:00 weekly 0.7 https://trial.medpath.com/news/three-apple-watches-get-fda-approval-for-sleep-apnea-detection-from-today-9to5mac 2024-09-16T15:09:00+00:00 weekly 0.7 https://trial.medpath.com/zh/news/three-apple-watches-get-fda-approval-for-sleep-apnea-detection-from-today-9to5mac 2024-09-16T15:09:00+00:00 weekly 0.7 https://trial.medpath.com/news/perioperative-durvalumab-with-neoadjuvant-chemo-boosts-survival-in-cisplatin-eligible-mibc 2024-09-16T15:08:24+00:00 weekly 0.7 https://trial.medpath.com/zh/news/perioperative-durvalumab-with-neoadjuvant-chemo-boosts-survival-in-cisplatin-eligible-mibc 2024-09-16T15:08:24+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-lebrikizumab-for-patients-aged-12-and-older-with-moderate-to-severe 2024-09-16T15:05:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-lebrikizumab-for-patients-aged-12-and-older-with-moderate-to-severe 2024-09-16T15:05:26+00:00 weekly 0.7 https://trial.medpath.com/news/ipsen-shelves-cabometyx-combo-in-prostate-cancer-after-phase-iii-miss 2024-09-16T15:00:26+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ipsen-shelves-cabometyx-combo-in-prostate-cancer-after-phase-iii-miss 2024-09-16T15:00:26+00:00 weekly 0.7 https://trial.medpath.com/news/apac-roundup-cdsco-releases-draft-guidelines-on-good-clinical-practices-for-consultation-raps 2024-09-16T14:59:57+00:00 weekly 0.7 https://trial.medpath.com/zh/news/apac-roundup-cdsco-releases-draft-guidelines-on-good-clinical-practices-for-consultation-raps 2024-09-16T14:59:57+00:00 weekly 0.7 https://trial.medpath.com/news/leap-012-pembrolizumab-plus-lenvatinib-added-to-tace-improved-progression-free 2024-09-16T14:51:36+00:00 weekly 0.7 https://trial.medpath.com/zh/news/leap-012-pembrolizumab-plus-lenvatinib-added-to-tace-improved-progression-free 2024-09-16T14:51:36+00:00 weekly 0.7 https://trial.medpath.com/news/positive-trial-demonstrates-safe-breastfeeding-during-endocrine-therapy-break-for-hr-breast-cancer-patients 2024-09-16T14:48:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/positive-trial-demonstrates-safe-breastfeeding-during-endocrine-therapy-break-for-hr-breast-cancer-patients 2024-09-16T14:48:16+00:00 weekly 0.7 https://trial.medpath.com/news/fda-approves-tecentriq-hybreza-cancer-therapy-advisor 2024-09-16T14:47:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/fda-approves-tecentriq-hybreza-cancer-therapy-advisor 2024-09-16T14:47:48+00:00 weekly 0.7 https://trial.medpath.com/news/ocrevus-zunovo-now-approved-in-us-to-treat-relapsing-ms-ppms 2024-09-16T14:44:02+00:00 weekly 0.7 https://trial.medpath.com/zh/news/ocrevus-zunovo-now-approved-in-us-to-treat-relapsing-ms-ppms 2024-09-16T14:44:02+00:00 weekly 0.7 https://trial.medpath.com/news/sanofi-shipping-beyfortus-r-in-us-to-help-protect-babies-against-rsv-disease 2024-09-16T14:43:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sanofi-shipping-beyfortus-r-in-us-to-help-protect-babies-against-rsv-disease 2024-09-16T14:43:07+00:00 weekly 0.7 https://trial.medpath.com/news/new-trial-to-test-potential-treatment-for-chronic-kidney-disease 2024-09-16T14:43:06+00:00 weekly 0.7 https://trial.medpath.com/zh/news/new-trial-to-test-potential-treatment-for-chronic-kidney-disease 2024-09-16T14:43:06+00:00 weekly 0.7 https://trial.medpath.com/news/velsera-technology-paves-the-way-for-advanced-cancer-diagnostics-with-fda-approval-of 2024-09-16T14:42:48+00:00 weekly 0.7 https://trial.medpath.com/zh/news/velsera-technology-paves-the-way-for-advanced-cancer-diagnostics-with-fda-approval-of 2024-09-16T14:42:48+00:00 weekly 0.7 https://trial.medpath.com/news/novartis-breast-cancer-drug-found-to-cut-disease-recurrence-investopedia 2024-09-16T14:33:42+00:00 weekly 0.7 https://trial.medpath.com/zh/news/novartis-breast-cancer-drug-found-to-cut-disease-recurrence-investopedia 2024-09-16T14:33:42+00:00 weekly 0.7 https://trial.medpath.com/news/risk-for-second-primary-cancer-may-be-no-higher-with-car-t-cell-versus-standard-of-care 2024-09-16T14:32:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/risk-for-second-primary-cancer-may-be-no-higher-with-car-t-cell-versus-standard-of-care 2024-09-16T14:32:07+00:00 weekly 0.7 https://trial.medpath.com/news/sec-form-424b5-filed-by-inmune-bio-inc-quantisnow 2024-09-16T14:26:45+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sec-form-424b5-filed-by-inmune-bio-inc-quantisnow 2024-09-16T14:26:45+00:00 weekly 0.7 https://trial.medpath.com/news/trishula-therapeutics-presents-positive-results-from-phase-1-trial-of-ttx-030-in-first-line-metastatic-pancreatic-cancer-patients 2024-09-16T14:09:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/trishula-therapeutics-presents-positive-results-from-phase-1-trial-of-ttx-030-in-first-line-metastatic-pancreatic-cancer-patients 2024-09-16T14:09:08+00:00 weekly 0.7 https://trial.medpath.com/news/neoadjuvant-and-adjuvant-pembrolizumab-extends-survival-in-early-stage-tnbc 2024-09-16T14:03:10+00:00 weekly 0.7 https://trial.medpath.com/zh/news/neoadjuvant-and-adjuvant-pembrolizumab-extends-survival-in-early-stage-tnbc 2024-09-16T14:03:10+00:00 weekly 0.7 https://trial.medpath.com/news/pfizer-drug-treating-fatal-weight-loss-in-cancer-patients-found-effective-investopedia 2024-09-16T13:57:16+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pfizer-drug-treating-fatal-weight-loss-in-cancer-patients-found-effective-investopedia 2024-09-16T13:57:16+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-2024-pfizer-s-cachexia-drug-provides-meaningful-weight-gain-clinical-trials-arena 2024-09-16T13:56:08+00:00 weekly 0.7 https://trial.medpath.com/zh/news/esmo-2024-pfizer-s-cachexia-drug-provides-meaningful-weight-gain-clinical-trials-arena 2024-09-16T13:56:08+00:00 weekly 0.7 https://trial.medpath.com/news/apple-watch-sleep-apnea-detection-gets-fda-approval-techcrunch 2024-09-16T13:48:07+00:00 weekly 0.7 https://trial.medpath.com/zh/news/apple-watch-sleep-apnea-detection-gets-fda-approval-techcrunch 2024-09-16T13:48:07+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-j-j-cues-up-phase-3-for-rybrevant-in-colorectal-cancer-pharmaphorum 2024-09-16T13:36:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/esmo-j-j-cues-up-phase-3-for-rybrevant-in-colorectal-cancer-pharmaphorum 2024-09-16T13:36:22+00:00 weekly 0.7 https://trial.medpath.com/news/apple-watch-s-sleep-apnea-notification-feature-granted-fda-approval-tom-s-guide 2024-09-16T13:34:37+00:00 weekly 0.7 https://trial.medpath.com/zh/news/apple-watch-s-sleep-apnea-notification-feature-granted-fda-approval-tom-s-guide 2024-09-16T13:34:37+00:00 weekly 0.7 https://trial.medpath.com/news/esmo-2024-pfizer-s-cachexia-drug-provides-meaningful-weight-gain-yahoo-finance 2024-09-16T13:31:27+00:00 weekly 0.7 https://trial.medpath.com/zh/news/esmo-2024-pfizer-s-cachexia-drug-provides-meaningful-weight-gain-yahoo-finance 2024-09-16T13:31:27+00:00 weekly 0.7 https://trial.medpath.com/news/alliance-unveils-phase-iii-cabozantinib-trial-results-at-esmo-mirage-news 2024-09-16T13:30:47+00:00 weekly 0.7 https://trial.medpath.com/zh/news/alliance-unveils-phase-iii-cabozantinib-trial-results-at-esmo-mirage-news 2024-09-16T13:30:47+00:00 weekly 0.7 https://trial.medpath.com/news/vera-therapeutics-to-host-in-person-r-d-day-in-new-york-to-discuss-potential-indication 2024-09-16T13:30:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vera-therapeutics-to-host-in-person-r-d-day-in-new-york-to-discuss-potential-indication 2024-09-16T13:30:30+00:00 weekly 0.7 https://trial.medpath.com/news/biovie-secures-all-scientific-approvals-needed-to-receive-additional-12-6-million-of-grant 2024-09-16T13:30:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/biovie-secures-all-scientific-approvals-needed-to-receive-additional-12-6-million-of-grant 2024-09-16T13:30:30+00:00 weekly 0.7 https://trial.medpath.com/news/boehringer-s-nerandomilast-meets-primary-endpoint-in-pivotal-phase-iii-fibroneertm-ipf-study 2024-09-16T13:29:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/boehringer-s-nerandomilast-meets-primary-endpoint-in-pivotal-phase-iii-fibroneertm-ipf-study 2024-09-16T13:29:56+00:00 weekly 0.7 https://trial.medpath.com/news/pds-biotech-announces-updated-data-from-versatile-002-phase-2-study-in-hnscc 2024-09-16T13:26:55+00:00 weekly 0.7 https://trial.medpath.com/zh/news/pds-biotech-announces-updated-data-from-versatile-002-phase-2-study-in-hnscc 2024-09-16T13:26:55+00:00 weekly 0.7 https://trial.medpath.com/news/cvkd-new-blood-thinner-ready-for-phase-3-initiating-coverage-of-cadrenal-therapeutics-inc 2024-09-16T13:24:34+00:00 weekly 0.7 https://trial.medpath.com/zh/news/cvkd-new-blood-thinner-ready-for-phase-3-initiating-coverage-of-cadrenal-therapeutics-inc 2024-09-16T13:24:34+00:00 weekly 0.7 https://trial.medpath.com/news/nimmune-biopharma-to-participate-in-ubs-virtual-biotechnology-private-company-symposium 2024-09-16T13:19:09+00:00 weekly 0.7 https://trial.medpath.com/zh/news/nimmune-biopharma-to-participate-in-ubs-virtual-biotechnology-private-company-symposium 2024-09-16T13:19:09+00:00 weekly 0.7 https://trial.medpath.com/news/apple-watch-s-sleep-apnea-detection-feature-receives-fda-approval-macrumors 2024-09-16T13:12:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/apple-watch-s-sleep-apnea-detection-feature-receives-fda-approval-macrumors 2024-09-16T13:12:39+00:00 weekly 0.7 https://trial.medpath.com/news/vivtex-enters-new-research-agreement-with-equillium-to-develop-gi-targeted-formulations 2024-09-16T13:07:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/vivtex-enters-new-research-agreement-with-equillium-to-develop-gi-targeted-formulations 2024-09-16T13:07:15+00:00 weekly 0.7 https://trial.medpath.com/news/second-generation-of-i-spy-2-trial-design-is-driving-the-precise-in-precision-medicine 2024-09-16T13:07:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/second-generation-of-i-spy-2-trial-design-is-driving-the-precise-in-precision-medicine 2024-09-16T13:07:15+00:00 weekly 0.7 https://trial.medpath.com/news/t2-biosystems-receives-fda-clearance-to-market-the-t2candida-panel-for-pediatric-patients 2024-09-16T13:07:15+00:00 weekly 0.7 https://trial.medpath.com/zh/news/t2-biosystems-receives-fda-clearance-to-market-the-t2candida-panel-for-pediatric-patients 2024-09-16T13:07:15+00:00 weekly 0.7 https://trial.medpath.com/news/sanofi-shipping-beyfortus-r-in-us-to-help-protect-babies-against-rsv-disease-new 2024-09-16T13:04:33+00:00 weekly 0.7 https://trial.medpath.com/zh/news/sanofi-shipping-beyfortus-r-in-us-to-help-protect-babies-against-rsv-disease-new 2024-09-16T13:04:33+00:00 weekly 0.7 https://trial.medpath.com/news/shuttle-pharma-expands-clinical-trial-site-enrollment-for-phase-2-of-ropidoxuridine-stock-titan 2024-09-16T13:01:22+00:00 weekly 0.7 https://trial.medpath.com/zh/news/shuttle-pharma-expands-clinical-trial-site-enrollment-for-phase-2-of-ropidoxuridine-stock-titan 2024-09-16T13:01:22+00:00 weekly 0.7 https://trial.medpath.com/news/t2-biosystems-receives-fda-clearance-to-market-the-t2candida-panel-for-pediatric-patients 2024-09-16T13:01:19+00:00 weekly 0.7 https://trial.medpath.com/zh/news/t2-biosystems-receives-fda-clearance-to-market-the-t2candida-panel-for-pediatric-patients 2024-09-16T13:01:19+00:00 weekly 0.7 https://trial.medpath.com/news/final-results-from-cabinet-phase-iii-trial-reinforce-efficacy-benefits-of-cabometyx-tradingview 2024-09-16T12:53:30+00:00 weekly 0.7 https://trial.medpath.com/zh/news/final-results-from-cabinet-phase-iii-trial-reinforce-efficacy-benefits-of-cabometyx-tradingview 2024-09-16T12:53:30+00:00 weekly 0.7 https://trial.medpath.com/news/final-results-from-cabinet-phase-iii-trial-reinforce-efficacy-benefits-of-cabometyx-r-in-ipsen 2024-09-16T12:52:56+00:00 weekly 0.7 https://trial.medpath.com/zh/news/final-results-from-cabinet-phase-iii-trial-reinforce-efficacy-benefits-of-cabometyx-r-in-ipsen 2024-09-16T12:52:56+00:00 weekly 0.7 https://trial.medpath.com/news/don-t-count-out-cipher-pharma-research-capital-says-cantech-letter 2024-09-16T12:52:39+00:00 weekly 0.7 https://trial.medpath.com/zh/news/don-t-count-out-cipher-pharma-research-capital-says-cantech-letter 2024-09-16T12:52:39+00:00 weekly 0.7 https://trial.medpath.com/news/gsk-iteos-score-phase-ii-win-for-jemperli-tigit-combo-in-nsclc-biospace 2024-09-16T12:52:21+00:00 weekly 0.7 https://trial.medpath.com/zh/news/gsk-iteos-score-phase-ii-win-for-jemperli-tigit-combo-in-nsclc-biospace 2024-09-16T12:52:21+00:00 weekly 0.7